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                                                     Introduction: 
 
As  per    GOLD  2017  guidelines, chronic   obstructive    pulmonary   disease  is  a 
 
common , preventable  and  treatable  disease   characterized  by  a  persistent    
 
respiratory   symptoms   and   airflow  limitation    due  to  airway  and / or   
 
alveolar  abnormalities  usually  caused  by  a  significant  exposure   to   noxious    
 
particles   or   gases.  COPD   represents   an   important   public   health   challenge   and    
 
is  a  major  cause  of  chronic  morbidity  and  mortality  throughout  the  world.  COPD  
 
is   currently   the   fourth   leading   cause   of   death    in  the  world (1)    but  it  is   
 
projected  to  cause  over  6  million  deaths    by  2020  and  thereby  becomes  a third   
 
leading  cause  of  death  in  the  world. 
 
 
COPD  patients   frequently   have  concomitant  cardiovascular  disease, skeletal  muscle   
 
dysfunction ,  metabolic  syndrome, osteoporosis , depression, anxiety and  lung   
 
cancer. These  comorbidities  can  independently  influence the  mortality  and   
 
hospitalizations  in  COPD  patients(GOLD  2017).  
. 
 
COPD  and  cardiovascular  disease  (CVD)  are  leading  causes  of  mortality  globally.  
 
The  prevalence  of  cardiovascular  disease  in  COPD  is  around  28%- 70%(2).  
 
Cardiovascular  diseases  are  the  major  contributor  of  morbidity  and  mortality  in   
 
patients  with  COPD.(3)(4)(5).  Systemic   inflammatory   changes   related    with   
 
COPD   may   independently  increase  the  risk  of  cardiovascular  diseases(6). 
 
 
Understanding  the  association  between  these   two  disease  entities  may  enable   
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improved   Cardiovascular  disease   risk  prediction  in  patients  with  COPD  by   
 
identifying  those  individuals  at  higher  risk  of  cardiovascular   disease   morbidity   
 
and  mortality. This  understanding  may  also  provide  an  opportunity  to  develop   
 
targeted  therapies  for  the  subset  of  patients  with  CVD  and  COPD  as  the  nature   
 
of  inflammation  may  be  the   same. 
 
Every  10%  decrease  in  FEV 1  increases  all  cause  mortality  by  14%,  cardiovascular  
mortality  by  28%,  and  nonfatal  coronary  event  by  almost  20%,  after  adjustments  
for  relevant  confounders  such  age,  sex,  smoking  status  and  treatment   
assignment.(7) 
 
In  2016  it  was  estimated  that  about  59.1  lakh  people  in  urban  areas  and  163 lakh   
people  in  rural   areas  in  India  suffered   from  COPD(8).  The  prevalence   of  obesity   
and  metabolic  syndrome(MetS)  is  rapidly  increasing  in  India  and  approximately    
about  one-third  of  the  urban  populations   have MetS.(9). Metabolic  syndrome  is   
found  to  be  twice  more  common  in  COPD  when  compared  to the  general   
population. Several  studies  from  different  parts  of  the  world  have  shown   a   
prevalence of  25.6-60.9%  of  metabolic  syndrome  in  patients  with  COPD( 10)(11). 
 
Fabbri et al.(13)  proposed  COPD  as  a  chronic  inflammatory  disorder(12).  Several   
etio-Pathogenic  mechanisms  have  been  proposed  as  a  possible  link  between  COPD   
and Metabolic  disorders  that  include  systemic  inflammation,  adipose  tissue   
inflammation  and  physical  inactivity. 
 
Metabolic  syndrome  has  been  identified  as  an  independent  risk  factor  for   
worsening  respiratory  symptoms,  increasing  lung  function  impairment,  pulmonary   
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hypertension  and   poor  exercise  tolerance  in   COPD  patients(14). 
 
Oxidative  stress  and  chronic  hypoxia  in  COPD  patients  may  contribute  to  the  
development  of  CVD,  but  the  most  attributing   factor  is  thought  to  be  the   
systemic  inflammation   and  also   airway  inflammation   may  induce   spill  over    
systemic  inflammation   which  is  responsible  for   progression   of  atherosclerosis.  
 
Carotid   atherosclerosis   strongly  correlates  with  coronary  atherosclerosis (15)  and   
carotid  intima-media  thickness (CIMT)  measured   by  carotid  doppler  ultrasound  is   
an  effective,  validated  method  for  evaluating   carotid   atherosclerosis (16). Both   
COPD  and  metabolic  syndrome  contributes  to  atherosclerosis  by  systemic   
inflammation  and  thereby  contributing  for  increased  cardiovascular  diseases. 
 
Increased   CIMT  is  associated  with  increased  total  and  cardiovascular  mortality  in  
patients  with  COPD  suggesting  that  CIMT  measurement   may   be  a  good  
biomarker  to   assess   the   cardiovascular   morbidity   and  mortality   in   these    
patients(17). 
 
Since  COPD  is  a  multicomponent   disease  with  inflammation  at  its  core  leading   
to  mortality ,  diagnosing    metabolic   syndrome   and  measuring  carotid  intima   
media   thickness  (CIMT) which  is  a  marker  of   subclinical   atherosclerosis   can   
help  us   to   predict   the  cardiovascular   diseases   in   advance. 
 
Comorbidities    associated    with   COPD   is   an   area   of   research   and  there  are   
Not   many   studies   done   in   india  to  establish  the  association  of   COPD  with 
Metabolic  syndrome   and   carotid   intima   media   thickness. 
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                                             REVIEW  OF  LITERATURE: 
 
COPD  AND  IT’S  COMORBIDITIES: 
 
Extrapulmonary    comorbidities   influence   the   prognosis   of   patients   with   COPD.  
Tobacco   smoking  is  a  common   risk  factor   for   many  comorbidities,  including  
coronary   heart  disease,  heart  failure  and   lung cancer(18). Various   comorbidies   are 
 
 Pulmonary  hypertension 
 Malnutrition 
 Coronary  artery  disease  
 Heart  failure 
 Lung  cancer 
 Systemic  venous  thromboembolism 
 Anxiety & depression 
 Peripheral  muscle  wasting 
 Osteoporosis 
 Obesity 
 Metabolic  syndrome 
 Diabetes & hypertension 
 Cardiac Arrythmias 
 Sleep  disturbances 
 Obstructive  sleep  apnea 
 Peripheral  vascular  diseases 
 Cognitive  impairment 
 Sexual  dysfunction 
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SYSTEMIC  INFLAMMATION  IN  COPD: 
 
Chronic  obstructive  pulmonary  disease  is  characterised  by  a  chronic  inflammation  
in  the  pulmonary  tissue.  The  extent  of  the  inflammatory  reaction  is  correlated   
with  the  severity  of  the  disease. 
 
Gang et al.(20)  reported  a  meta-analysis  of  14  reports  which  confirmed  a  strong  
Association  between  COPD  and  inflammatory  markers  such  as  CRP,  fibrinogen,  
and  TNF-α(19). Pulmonary  inflammatory   biomarkers   in   induced   sputum,  
bronchoalveolar   lavage,   endobronchial   biopsy   have  also  been   studied  to   
correlate  the   association  between   COPD  and  systemic  manifestation. 
 
The  increase  in  circulating  inflammatory  markers  in  COPD  has  been  considered  as  
a  part  of  the “spill over”  of  the  inflammatory  mediators  from  the  pulmonary  
compartment  which  is  primarily  responsible  for  systemic  inflammation. The  role  of  
the  spill  over  hypothesis  has  been  further  emphasized  in  recent  studies  by   
studying   the  relationship  between  the  various  inflammatory  biomarkers  and  
pulmonary  tissue-derived  proteins   such   as   surfactant  D-derived  proteins  from  
pneumocyte -II.  A  recent   study   by   Kim et al.   studied   the   candidate   Single  
Nucleotide Polymorphism(SNP)  of  two   pneumoproteins   clara  cell  secretory  protein   
(CC16)   and   surfactant   protein D  (SP-D)  which  appear  to  be  strongly  correlate   
with  COPD.  However,  the  roles  of such  biomarkers  are  yet  to  be  fully   
established(21). 
 
The  possible  mechanism  proposed  in  spill  over  hypothesis  are(23) 
1) Leakage  of  reactive  oxygen  species  and  stress  induced  cytokines  directly  
into  the  peripheral  blood.  
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2) Preactivation  of  peripheral  blood  leukocytes  that  can  result  in  aberrant  
homing and  activation  of  inflammatory  cells  in  distant  tissues.  
3) Liberation  of  proinflammatory  mediators  by  leukocytes  and  stromal  cells 
present  in  the  pulmonary  tissues  during  progression  of  the   disease. 
 
Adipose  tissue  inflammation  has  been  proposed  to  be  one  of  the  important  
Contributors  to  systemic  inflammation  in  obese  COPD  patients. Inflammation  of  
Large  adipocytes  are  associated  with  an  increased  production  of  pro-inflammatory  
adipokines  IL-6,  TNF-α,  PAI-1  and  leptins.  Inflammation  of  adipose  tissue  has  an  
adverse  effect  on  insulin  signaling  pathways.  Relationships  have  been  observed  
between  high  adiposity,  insulin  resistance  and  the  adipose  tissue  expression  of  
macrophage cell surface receptor CD68.  It  plays  an  important  role  in  whole  body   
insulin  resistance  in   COPD patients(22).   
 
In  addition  to  its  contribution  to  the  extrapulmonary  effects  of  COPD,  the   
intensity  of  the  systemic   inflammation  is  directly   related   to   the  poorer  quality   
of  life,  airflow  limitation  and  exercise  intolerance  observed  in  COPD.(24) Thus   
COPD can  cause  low  grade  systemic  inflammation  by  hypoxia  and  various  other   
mechanisms   and  systemic  inflammation  in  turn  can  adversely   affects   the  clinical   
and  functional  characteristics  of  COPD. 
 
Heart disease and systemic and pulmonary vascular diseases in COPD 
Vascular  and  heart  diseases  are  among  the  most  important  comorbidities  observed  
in  COPD,  because  they  have  a  direct  impact  on  patient  survival. The  
pathophysiological  mechanisms  underlying  the  vascular  alterations  observed  in   
COPD  appear  to  be  mainly  mediated  by  endothelial  dysfunction  and  coagulopathy. 
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Endothelial dysfunction and COPD 
The systemic  inflammation  observed  in  COPD  seems  to  be  the  key  determinant for  
 
the  development  of  pulmonary   and  systemic  endothelial  dysfunction, although  the  
 
precise  pathophysiological  mechanisms  are unknown. Circulating  endothelial  
 
progenitor  cells (CEPCs), which plays an important  role in  maintaining  endothelial   
 
cell  integrity  appears  to  be  reduced  in  the systemic  circulation  and   increased  in   
 
the  pulmonary   circulation  of  patients  with COPD (25)  
 
Coagulopathy and COPD 
The systemic  inflammation  present  in  COPD  appears  to  induce  a “pro-coagulant”  
 
state.  In  the  basal  state,  COPD  patients  exhibit  abnormally  high  levels  of  tissue  
 
factor (tissue  factor  pro-coagulant  activity)  and  Factor VIIa(26),  and  their  fibrin  
 
clots  are  resistant  to  lysis . After  2 h  of  artificial  hypoxaemia,  compared  to  non- 
 
hypoxic  controls,  COPD  patients  have  abnormally  elevated  levels  of  circulating  
 
thrombin–antithrombin  complex  and  prothrombin  activation  fragments,  with  a  
 
parallel  elevation  in  interleukin (IL)-6 . 
 
Coronary heart disease  and  COPD 
 
Epidemiological association 
Coronary  heart  disease  and  COPD  share  the  same  main  risk  factor,  i.e. smoking.  
 
The   impact  of  obstructive  airway  disease, defined  by  a  decrease  in  the  ratio  of   
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forced  expiratory  volume  in  1 s (FEV1) to forced  vital  capacity (FVC),  is  less  clear- 
 
cut,  as  it  only  increases  the  risk  of  a  coronary   event  by  30%.  However,  for   
 
every  10%  decrease  in  FEV1,  all-cause mortality  increases  by  14%,  cardiovascular   
 
mortality  increases  by  28%  and  the  frequency  of  non-fatal  coronary  events   
 
increases  by  20%(7).  The  link  between  COPD  and  coronary  heart  disease  is   
 
independent  of  any  other  confounding  coronary  risk  factors,  namely  smoking   
 
status,  cholesterol,  systemic  hypertension  and  body  mass  index (BMI)(27). 
 
Shared  pathophysiological  mechanisms: 
 
In  coronary  heart  disease,  the  activation  of  immune  cells  in  the  atheromatous  
plaque  induces  the  production  of  cytokines  such  as  interferon-γ,  IL-1,  tumour  
necrosis  factor (TNF)-α,  IL-6  and  acute-phase  inflammatory  proteins (fibrinogen, C- 
reactive protein (CRP)  and  amyloid  protein) .  The  same  mediators  are  involved  in  
the  inflammatory  reaction  observed  in  the  bronchus  in  COPD. In  addition  to  these  
shared  pathophysiological  determinants,  the  presence  of  COPD  could  contribute  to  
the  development  of  cardiovascular  disease  through  hypoxia,  systemic  inflammation  
and  oxidative  stress (28),  and  through  impaired  vasodilatory  capacity. 
 
Coexistence  of  COPD  and  coronary  heart  disease  worsens  the  prognosis  of  both 
diseases: 
 
 Coronary  heart  disease  often  goes  unrecognised  in  COPD.  A  retrospective  study   
of  the  medical  records  of  897  COPD  patients  treated  between  2000  and  2003  was  
conducted  in  Akershus  University  Hospital  (Oslo, Norway) (29). The  records  of  827  
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(92%)  patients  included  an  ECG.  Sequelae  of  myocardial  infarction  were  found  on  
The  ECGs  of  229 (27.6%)  patients,  yet  only  30%  of  these  patients  had  a  
recognized  history  of  myocardial  infarction.  Follow-up  of  the  cohort  until  2005  
revealed  the  negative  impact  of  a  high  ECG-based  cardiac  infarction  injury  score  
on  their  survival. 
 
 
The  systemic  inflammatory  reaction  might  play  a  role  in  the  increased  coronary  
risk  in  patients  with  COPD. The  effect  of  COPD  medication  on  cardiovascular  
events  is  not  yet  completely  clear. The  analysis  of  the  data  collected  during  the  
TORCH  (Towards a Revolution in COPD Health)(30)  study  showed  no  increase  in  
Cardiovascular  events  in  patients  with  moderate-to-severe  COPD  receiving  
Salmeterol  alone  or  in  combination  with  oral  steroid  therapy.   The  possibility  that   
tiotropium   provokes  cardiovascular  adverse  effects  continues  to  be  raised ,  with a    
relationship  between  the  dose  placed  in  the  inhaler  and  the  risk  of  adverse  effects   
having  recently  been  suggested. 
 
 
HEART  FAILURE  AND  COPD: 
 
In  a  recent  study,  transthoracic   echocardiography   was   prospectively   performed  in  
 
342   COPD  patients  3  months  after  their  first  exacerbation.  Significant  cardiac  
 
Alterations  were  present  in  64%  of  patients, 27%  left- and  48% right-heart  
 
disorders.  In  63%  of  these  patients,  cardiac  disease  was  not  known(31). 
 
A  meta-analysis  of  12  analysable  studies,  published  in  2006, revealed  the   
prevalence   of   heart   failure  among  patients  experiencing  an  exacerbation  was  as  
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high  as  46%  versus  3.8–16%  in  those  with  stable  disease(32).  The  importance  of   
this  combination  was  confirmed  in  a  cohort  study  including  >45 000  patients  with  
COPD  and  a sex-  and  age-matched  healthy  population  of  the  same  size,  whose  
end-points  were  hospitalisation  and  cardiovascular  mortality  rates  over  a  follow-up  
period  of  almost  3  years. 
 
IMPACT  OF  COPD  ON  HEART  FAILURE: 
 
One  of  the  first  studies   followed  800  patients  with  heart  failure  for  5  years  and  
showed  that  survival  was  significantly  lower  in  the  group  with  concomitant   
COPD. The  studies  based  on  the  Norwegian  Heart  Failure  Registry,  including  4132  
Patients  with  heart  failure  from  22  cardiology  centres,  followed  for  nearly  8  years,  
Demonstrated  a  significantly  higher  proportion  of  deaths  in  patients  with  
Concomitant   COPD (32.6% versus 37.0%; p=0.03).(33) 
 
Therefore  COPD is  an  independent  risk  factor  for  death  in  compromised  heart  
failure  patients,  and  the  coexistence  of  COPD  can  delay  the  diagnosis  of  heart  
failure. Beta  blockers  are  known  to  improve  the  survival  in  heart  failure, but   
underused  in  COPD  patients, with  the  fear  of  worsening  airflow  limitation.  
Switching  to  a  cardioselective  β-blocker  improves  spirometric  values,  without  
affecting  the  left  ventricular  ejection  fraction  or  New  York  Heart  Association  
functional class,  enabling  a  better  cardiac  prognosis  without  the  risk  of  
compromising   respiratory  function(34). 
 
COPD  AND  METABOLIC  SYNDROME: 
 Funakoshi et al. conducted  a  study  on  7189  Japanese  males  aged 45-88  years and    
found  that  patients  with  GOLD  staging  II - IV  have  a  high  probability  of   having  
co-existent  MetS  with  an  Odds  ratio  (OR)  of  1.33.  Among  the  various   
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components  of  MetS,  waist  circumference  (OR, 1.76; 95% CI, 1.24-2.50)  and  blood  
pressure  (OR, 1.37; 95% CI, 1.08-1.74)  showed  a  significant  association  with  airflow  
obstruction  of  GOLD  stage II-IV(35) 
 
The D.E.S.I.R. study  from  France  has  shown  that  the  MetS  occurs  more  frequently  
Among  current  smokers.  The  potential  mechanism  responsible  for  development  of  
COPD  and  the  MetS  in  a  smoker  is  primarily  due  to  systemic  inflammatory  
Response(36). 
 
The  Guangzhou  Bio  bank  cohort  study  demonstrated  that  the  risk  of  MetS  is  
 more common in those with significant airway obstruction 
   
Several  mechanisms  has  been  proposed  regarding  the  association  between  obesity  
and  airflow  limitation 
 (a) Decrease  in  chest  and  lung  compliance  
(b) Small  airway  dysfunction  and  expiratory  airflow  limitation  
(c) Variable  reduction  in  ventilator  muscle  strength  and  endurance  
(d) Increased  work  of  breathing 
Link  between  metabolic  syndrome  and  COPD  are  poorly  understood. The  proposed   
mechanisms  are 
 Common  pathophysiological  mechanisms – systemic  inflammation 
 Adipose  tissue  inflammation 
 Physical  inactivity 
 Hypogonadism 
 The  effect  of  steroids. 
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Steroids  affect  most  of  the  parameters  of  the  metabolic  syndrome.  The  traditional  
Clinical  features  of  steroid  overuse  are  diabetes,  hypertension,  dyslipidemia,  and  
weight  gain,  usually  presenting  as  central  obesity  with  redistribution  of  body  fat   
to  truncal  areas  and  dorsocervical  and  supraclavicular  fat  pads  and  the  classic  
moon  face(37). 
COPD  patients  with  the  MetS  have  a  more  severe  form  of  disease,  more  dyspnea,  
a  lower  FEV1  and  require  more  inhalational  glucocorticoids  to  control  the  disease. 
COPD  patients  with  MetS  have  higher  leptin  levels,  low  adiponectin  and  greater  
insulin  resistance.  Thus  this  group  of  COPD  subjects  can  be  further  stratified  into  
a  higher  risk  phenotype  which  requires  a  closer  follow-up(38) 
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COPD  AND  OBESITY: 
 
Steuten et al.(46) conducted   a   study  to  look  at  the  association  of  severity  of    
COPD And  BMI  among  317  subjects  in  the  Netherlands.  The  overall  prevalence   
of Obesity  was  18%  with  the  highest  prevalence  being  in  subjects  with  mild  to  
moderate  COPD (stages 1 and 2). 
 
In  patients  with  COPD,  obesity  has  an  unusual  impact  that  is commonly, referred  
As  “Reverse Epidemiology of Obesity”.  A meta–analysis  by  Cao et al.  analyzed  data  
on  22  studies  which  included  about  21,150  subjects.  It  was  found  that  patients  
with  a  lower  BMI  had  a  higher  mortality  rate  when  compared  with  normal  BMI 
subjects. The  relative  risk  for  mortality  is  found  to  be  decreased  in  overweight   
and  obese  patients  with  stages  3-4   while  it  increases  in  those  with  stage 1-2  
disease. The  weight  loss,  muscle  wasting  and  loss  of  fat  free  mass  is  more  
prominent in late stages 3 and 4 in COPD also known as Obesity Paradox(39). Thus  it  
indicates  that  both  cachexia  and  obesity  represent  the  two  extremes  of  a  spectrum  
of  metabolic  abnormalities  that  are  seen  in  patients  with  COPD  leading  to  adverse  
clinical  outcomes. 
 
Schols et al. (47)  have   prospectively  followed  up  412  stable  COPD  (stage -3 and 4)  
Subjects  for  2-5  years  or  till  the  point  of  death  whichever  was  earlier. The fat free  
mass ( FFM) was  found  to  be  a  better  predictor  of  mortality  irrespective  of  FM (fat  
mass) 
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COPD  AND  LIPOPROTEIN  METABOLISM: 
 
The  pattern  of  dyslipdemia  in  COPD  has  not  been  well  characterized.  The  
CONSISTE  study  is  a  study  to  assess  the  cardiovascular  risk  factors  in  COPD  
subjects.  COPD  subjects  had  the  highest  prevalence  of  IHD  (12.5% vs. 4.7%)  when  
compared  to  controls.  Dyslipidemia  was  found  in  48.3%  of  COPD  patients  and  
31.7%  among  controls.(48) 
 
In  the  Rotterdam  study(49)  the  effect  of  statins  was  prospectively  assessed  in   
COPD Patients  over  a  period  of  more  than  2  years.  Statins  are  associated  with  a  
Reduction  in  death  rate  by  36% .  Statins  have  many  pleiotrophic  effects  such  as  
anti-inflammatory   and    immunomodulatory   properties.  Statin  therapy  was  
associated  with  a  30%  decrease  in  risk  of  COPD  exacerbation(40). 
 
 
COPD  AND  DIABETES: 
 
The  prevalence  of  diabetes  in  COPD  is  approximately  about  3-12%(41).  Systemic  
inflammation  is  probably  an  important  contributory  factor  responsible  for  both  
COPD  and  diabetes  mellitus.  
 
The  nurses’  healthy  study:  a  prospective  study  over  an  8-year  period  had  showed  
that  COPD  patients  have  a  1.8%   relative  risk  of  developing  diabetes.  The   
markers  of  inflammation  such  as  IL-6,  TNF-α,  and  CRP  are  elevated  in  both  
COPD  and  diabetes  and  these  markers  are  elevated   to  a  greater  extent  in  
overweight  and  obese  COPD  patients(42) 
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Engstrom et al.  described  that  reduced  lung  function  is  an  important  risk  factor  for  
the  development  of  diabetes  in  COPD(50).  
 
Mannino et al.  shows  that  subjects  with  stage 3-4  had  a  higher  risk  for  developing  
diabetes  with  an  odds  ratio  of  1.5 (CI: 1.1-1.9)(51). 
 
COPD  AND  HYPERTENSION: 
 
The  incidence   of   hypertension   can   vary   from   6-50%  and  depends  upon  the  
Severity  of  airflow  of  obstruction.  A  recent  study  (INDACO  study)  demonstrated   
a  53%  incidence  of  hypertension. The   pathological   mechanisms  (43)  responsible  
for   hypertension   in   COPD  are  
 Hypoxia  related  vasoconstriction, 
 Free  radical  injury,  
 Endothelial  dysfunction,  
 Arterial  stiffness. 
 Control  of  hypertension  in  COPD  subjects  can  improve  the  cardiovascular-related  
Mortality. 
 
 
CAROTID  INTIMA  MEDIA  THICKNESS  AND  CARDIOVASCULAR   
EVENTS: 
 
Recent  American  Heart  Association  guidelines(52)  designated  carotid  intima-media  
thickness (CIMT)   is    a  class IIa  recommendation  for  cardiovascular  (CV)  risk  
assessment  in  asymptomatic  adults  at  intermediate  risk  of  cardiovascular  disease  
(CVD). 
16 
 
The  Kuoppio  Ischaemic  Heart  Disease  study(44)  showed  11%  increased  risk  of  
myocardial  infarction  with  each  0.1‐mm  incremental  increase  of  carotid  IMT. 
 Several  large  clinical  studies  like  the  Atherosclerosis  Risk  In  Communities study,   
the  Cardiovascular  Health  Study,  the  Rotterdam  Study,  the  Malmö  Diet  and   
Cancer Study,  and  the  Carotid  Atherosclerosis  Progression  Study  produced  similar  
results. 
 
European  Society  of   Cardiology(53)  recommends   ultrasound   scanning   of   the    
carotid arteries   to   detect   vascular   hypertrophy   or   atherosclerosis   as   a  class IIa  
recommendation   with   level  of  evidence B. 
 
Measuring   carotid  IMT  is  safe,  noninvasive  and  although  it  requires  some  
experience,  has  quite  high  reproducibility. 
 
 
COPD  AND  CAROTID  INTIMA  MEDIA  THICKNESS: 
 
Iwamoto et al.(54) reported  a  higher  mean  CIMT  in  male  smokers  with  airflow  
Obstruction  than  that  of  control  smokers  and  never  smokers,  indicating  that   
airflow  limitation  rather  than  smoking  per  se  is  associated  with  atherosclerosis. 
 
In the study by Gestel et al(55). the mean carotid wall IMT was 1.07 mm. Of  the patients  
Without  COPD,  23%  demonstrated  increased  CIMT,  whereas  32%  of  patients  with  
mild  COPD  and  36%  of  the  patients  with  moderate to severe  COPD  had  increased  
CIMT (P < 0.01) 
 
The Rotterdam study(56) also revealed a significantly higher  CIMT (≥2.5 mm) in  
participants with COPD than in those without COPD. Moreover, the CIMT  
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increased  significantly  with  the  severity  of  airflow  limitation. 
 
There is exaggerated subclinical atherosclerosis in smokers with airflow limitation,  
indicating that atherosclerotic change occurs early in the disease process of COPD.  
Systemic inflammation is predominantly associated with atheromatous plaque.  
Reduced lung function is associated with thickened IMT, but the underlying  
mechanism for  this  association  is  unclear. 
 
COPD  remained  a  significant  and  independent  predictor  of  carotid  plaqing   
After  adjusting  the  traditional  risk  factors  (P < 0.0001  odd  ratio  of  3.9  with  
95% CI 2.1 to 7.3)(45). 
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                          AIMS  AND  OBJECTIVES: 
 
PRIMARY  OBJECTIVE: 
TO  EVALUATE  THE  ASSOCIATION  OF  SUBCLINICAL   
ATHEROSCLEROSIS  IN  CHRONIC OBSTRUCTIVE   
PULMONARY  DISEASE  PATIENTS  WITH  METABOLIC   
SYNDROME. 
 
SECONDARY  OBJECTIVE: 
  
1. TO  EVALUATE  THE  ASSOCIATION  OF  SUBCLINICAL   
ATHEROSCLEROSIS  IN  DIFFERENT  STAGES  OF  COPD 
2.  TO  STUDY  THE  CLINICAL  AND  FUNCTIONAL   
DIFFERENCES  IN  COPD  PATIENTS  WITH  AND   
WITHOUT  METABOLIC  SYNDROME 
 
. 
. 
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                                   MATERIALS   AND   METHODS: 
 
STUDY  DESIGN: Prospective  Hospital  Based  Case  Control  Study 
STUDY CENTRE: Rajiv  Gandhi  Government  General Hospital,  
Madras Medical College, Chennai 
DURATION  OF  THE  STUDY: Jan 2017- August 2017 
SAMPLING  FRAME: 
 Patients  attending  OPD  of  Department  of  thoracic  medicine  in   
Rajiv  Gandhi  Government  General Hospital . 
 Age  and  sex  matched  apparently  healthy  volunteers  of   
patient’s  attendees  and  hospital  workers. 
 
SAMPLING  METHOD: Consecutive  Sampling. 
SAMPLE  SIZE: 
Two  sided  confidence  interval- 95% 
Power- 80% 
Ratio  of  Controls to  Cases: 2 
Percent  of  controls  Exposed: 25% 
Odds  ratio:3 
Cases(FLEISS): 42 
Controls(FLEISS): 84 
 
20 
 
OPERATIONAL  DEFINITIONS: 
Cases: Patients  diagnosed  as  a  case  of  COPD  as  per  GOLD  2017   
guidelines  and  those  who  satisfy  NCEP  ATP  3  criteria  of   
metabolic  syndrome. 
 
CONTROL  1:  Patients  diagnosed  as  a  case  of  COPD  as  per   
GOLD  2017  guidelines  and  those  who  do  not  satisfy  NCEP ATP 3   
criteria  of  metabolic  syndrome.   
 
CONTROL 2:  Age  and  sex  matched   apparently  healthy  volunteers   
of  patient’s  attendees  and  hospital  workers. 
 
SAMPLE  SELECTION: 
INCLUSION  CRITERIA: 
1. Willing  for  informed  written  consent  and willingness to  
participate  in  the  study. 
2. Attending  thoracic  medicine  department  OPD  and  diagnosed   
as  a case  of  COPD. 
3. Age  and  sex  matched  apparently  healthy  volunteers  of   
patients   attendees   and   hospital   workers 
4. Clinically  and  haemodynamically  stable  patients  who  can  
Undergo  the  needed  investigations and  testing. 
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5. Capable  of  completing  CAT &  MMRC questionnaire, six  minute walk  test and  
pulmonary  function  testing. 
    6. Patient  without  history  of  previous  anti-tuberculous  treatment. 
    7. Patients  seronegative  for  human  immunodeficiency  virus. 
    8.  Patients  without  active  pulmonary  tuberculosis. 
 EXCLUSION  CRITERIA: 
1.Not  willing  for  informed  written  consent  for  the  study. 
2.Known  case  of  cardiovascular  disease. 
3.COPD  patients  with  acute  exacerbation  in  past  6  weeks 
4.Known  cases  of  lung  diseases  other  than  COPD. 
5.Known  cases  of  inflammatory  bowel disease , vasculitis,  
rheumatological  diseases  and  other  inflammatory  conditions   
were  excluded. 
6. seriously ill  patients  those  who  cannot  perform  pulmonary   
function  testing  and  six  minute  walk  test 
           7.severe  hepatic  and  renal  dysfunction, malnutrition, severe  
            anaemia, malignancy and  mental illness. 
          8. Patients  who  are  on  oral  corticosteroids  or  an  any  other 
           Immunosuppressants.               
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ETHICAL  CLEARANCE: Applied 
INFORMED  CONSENT: Obtained  from   all  the  patients 
Diagnosis  of  COPD  was  based  on  symptoms,  physical  examination,   
and  presence  Of  risk  factors.  Diagnosis  was  confirmed  by  post- 
bronchodilator  spirometry  that  was  performed  15  min  after   
administration  of  four  doses  of  salbutamol  sulfate (100 μg). 
 
As  per NCEP ATP 3 ( 2005 REVISED definition) ,  metabolic  
syndrome is defined  as three  out  of  five  of  the  following  features,  
 
1.Obesity( waist circumference >=40 inches in males,>= 35 inches  in females),  
2.Hyperglycemia ( fasting glucose>=100mg/dl or on treatment),  
3.Hypertriglyceridemia ( triglyceride >= 150mg/dl or on treatment)  
4.Decreased HDL cholesterol( <40mg/dl(M), <50mg/dl(F) ) 
           5.Hypertension.( systolic >= 130mmHg or diastolic >= 85mm Hg)  
 
A reading of more than 0.8 mm was taken as increased  Carotid intima  
media  thickness  and  is  the  earliest  marker  of  atherosclerosis. 
 
Plaque  was  defined  as  CIMT  of  more  than  1.2 mm  and  was  at  
least 50% thicker than the neighboring segment. Presence  of plaqing in  
either of carotids was recorded as plaque present.  
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METHODOLOGY: 
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The  study  population  who   satisfied   the   inclusion  criteria  were  included  in the 
study. 
 
A  detailed  history  regarding  the   presenting   complaints  , past history, treatment  
history, smoking  history ,biomass  exposure, occupational  exposure and  alcoholism   
were  taken. 
 
History  regarding  the  comorbidities  like  Diabetes mellitus,  systemic  hypertension,  
coronary  artery  diseases,Bronchial  asthma, neurological  diseases  were  obtained. 
 
All  the  study  population  underwent  the  structured  clinical  examination  of  all  the   
systems. 
 
The  height  and  weight of the study population were  measured  in  light  indoor  clothes  
and  without  shoes. Body  mass  index  (BMI)  was  calculated. 
BMI(weight in kg /( height  in  meter )
2
 
18.5- 24.9: NORMAL 
25- 29.9  : OVERWEIGHT 
30- 35: OBESE 
>35 : MORBID  OBESE 
 
Blood  pressure  was  measured  in  right  arm  in  sitting  posture. Three  serial   
measurements  were  done  and  average  was  taken. 
 
Waist  circumference  was  determined  by  a  single  observer  using  a  tapeline  at  the  
midpoint  between  the  lowest  rib  and  the  iliac  crest. 
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After  an  overnight  fasting,  venous  blood  sample  (10 ml)  was  obtained.  Serum  
glucose, triglyceride and high-density lipoprotein (HDL)-cholesterol levels were  
measured  with  standard  methods  using  a  chemical  analyzer. 
 
Sputum  investigations, CXR  PA view , Complete  hemogram, renal  function  test, liver   
function  test  and  CT CHEST ( if needed)  were   done  in  all  the  subjects. 
 
ECG  and  ECHOCARDIOGRAPHY were  done  for  both  cases  and  controls. 
 
Arterial  blood  gas  analysis  was  done  for  cases  and  controls 1. 
. 
 
The COPD assessment test (CAT) is a validated questionnaire that is completed by the 
patient to assess and  quantify the  status of health and the symptom burden in COPD 
patients. In this study the questionnaire was translated to the the study site language and 
then translated back to English. It is composed of eight questions each presented as a six-
point (0-5) differential scale with a total score out of 40. The clinical impact of the 
disease is graded as follows: 
 
 0-10 – mild 
 11-20 – moderate 
 21-30 – severe 
 31-40 – very severe 
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Pulmonary  function  test  was done for all patients who satisfied the inclusion criteria. 
The test was performed  in accordance with the criteria set by the American Thoracic 
Society using Easyone Spirometer. The instrument was calibrated daily. The procedure 
was explained to all patients before the test. Any recent history of smoking, illness, 
medication were enquired and the height and weight were recorded. All participants were 
kept in the seated position for the procedure.  
 
All participants were instructed and demonstrated to hold the head in slightly elevated 
manner, position the mouthpiece and close lips, inhale completely and rapidly and then 
exhale maximally until no more air can be expelled. 
 
Instructions were repeated as necessary . Throughout the manoeuvre, subjects were 
encouraged to blast out and exhale using appropriate body languages and phrases. The 
test was stopped whenever they complained of distress or dizziness. The test was 
repeated till at least three trials with two acceptable and reproducible tests for both FEV1 
and  FVC were obtained. Measurements were made before and after atleast 15 minutes of 
two puffs of salbutamol (200 μg) administered using metered dose inhaler with a 
volumatic spacer. The parameters were recorded and partial reversibility if present was 
noted.  IF  post  bronchodilator  FEV1/FVC < 0.8  with  clinical  features  suggestive  of  
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COPD  with  appropriate  background  of  risk  factors, the  diagnosis  of  copd  was  
made.  GOLD  Staging  of   COPD  based  on  % FEV1  predicted  was  calculated. 
                FEV1 > 80%  predicted= mild  COPD (stage 1) 
                FEV1 50- 80% predicted = moderate  COPD( stage 2) 
                FEV1 30- 50% predicted= severe  COPD( stage 3) 
                FEV1 < 30% predicted= very  severe COPD( stage 4) 
Six minute walk distance was measured for all patients. The test was performed indoors 
in a 100 ft hallway (30 m length). The length was of the hallway was marked every 3m as 
well as the starting and ending point of each 60m lap. The turnaround points were 
marked with two small cones. 
All patients were prepared and appropriate clothing, footwear, walking aids were 
ensured. It was instructed to avoid vigorous exercise within 2 hours of beginning the 
test. Pulse, blood pressure and oxygen saturation were recorded before the start of the 
test. A wheel chair and water were kept nearby as a precautionary measure. 
After setting the timer to 6 minutes, all the patients were instructed to walk back and 
forth briskly in the designated hallway for as far as possible for 6 minutes. Incase of any 
respiratory distress, they were permitted to slow down, lean on the wall, stop and rest 
as and when necessary. The test was resumed as soon as they were able to walk again. 
During the test, all the patients were verbally encouraged and motivated to keep 
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walking. As soon as the timer rang denoting 6 minutes, patients were instructed to stop 
where they were and the spot was marked. The total number of laps covered with the 
additional distance covered in the last lap was recorded. In case the test was stopped 
prematurely, the distance walked till then was recorded along with reason for stopping.  
BODE  index  is  a  multidimensional  marker  of  a  disease  taking  into  consideration  
the  systemic  nature  of  disease. It  helps  us  to  predict  the  4  year  survival  prediction 
rate  among  COPD  patients. 
B- BMI (weight in kg/ (height  in  meter)
2 
O-FEV1%   predicted  after  bronchodilator. 
D- MMRC  Dyspnea  scale 
E- EXERCISE  capacity( 6 minute walking  distance) 
              BODE  INDEX    4  YEAR  SURVIVAL  PREDICTION RATE 
                 0-2         80% 
                3-4         67% 
               5-6         57% 
              7-10         18% 
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Pulmonary  hypertension  and  right  ventricular  dysfunction  were  assessed  by  2D  
transthoracic  echocardiography.   
Bilateral  carotid  arteries  were  evaluated  by  a  single  trained   radiologist  blind  to  
clinical  evaluation  using  a  B-mode  ultrasonography (General Electric, Logic 3 Expert  
Ultrasound)  with  a  5–10 MHz  multi  frequency  linear  probe.  The  luminal  diameters  
Of  the  bilateral  common  carotid  arteries  and  internal  carotid  arteries  were  
Measured  between  the  bright  internal  layers  of  the  parallel  vessel  walls. 
 
 Intima-media  thickness  was  defined  as  the  distance  between  the  edge  of  the  
luminal  echo  and  media/adventitia  layer.  All  subjects  had  IMT  measurements  at   
the  proximal,  middle  and  distal  levels  of  both  common  carotid  arteries.  The  mean  
thickness  at  these  three  points  was  calculated  for  each  carotid  artery  and  the  
highest  value  was  accepted  as  IMT.  Measurements  with  a  focal  IMT  of   0.8 mm  
or  greater  were  defined  as  increased  IMT. 
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                                              STATISTICAL  ANALYSIS: 
 
The data were expressed as the mean and standard deviation (SD) or the median and 
interquartile range. The study groups were compared using an unpaired t test and one-
way ANOVA for continuous variables and Mann Whitney U-test for variables with non-
normal distribution. Chi-square analysis was used for the comparison of categorical data. 
Univariate correlation analysis between IMT & FEV1%, was performed by calculating 
Pearson’s or Spearman’s correlation coefficients.  
Furthermore, a multivariate logistic regression model was utilized to analyze the 
association between the presence of COPD and MetS. A multivariate linear regression 
model was utilized to analyze the relationship between the presence of COPD and IMT. 
These regression models were used to control the potential confounding factors (namely: 
age, BMI, smoking, hypertension, FPG, triglyceride, HDL-cholesterol). 
 All data were analyzed by SPSS 16.0 software package. p ≤ 0.05 was considered to be 
statistically  significant. 
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                                              RESULTS: 
 
We  had  included  126  subjects  in  our  study. All  of  them  had  satisfied  inclusion  
and  exclusion  criteria. Among  them,  84  patients  were  diagnosed  as  case  of   COPD  
as  per  GOLD  2017  guidelines. Age  and  sex  matched  healthy volunteers  of  around  
42   were  taken. In  all  the  subjects, metabolic  syndrome  was  diagnosed  as  per  
NCEP  ATP  3  criteria.COPD  with metabolic  syndrome  was  taken  as  cases.  COPD  
without  metabolic  syndrome  was  taken as  control 1. Age and  sex  matched  healthy  
volunteers  were  taken  as  control  2. Control  2  was  further  divided  into  control  with 
metabolic  syndrome  and  control   without  metabolic  syndrome. 
GENDER  DISTRIBUTION  OF  STUDY  POPULATION: 
 
Figure 1: GENDER  DISTRIBUTION  IN DIFFERENT  GROUPS 
 
By  consecutive  sampling  in all  the  study  groups,28  males  and  14  females  were  
obtained  and  they  were  included  in the  study. 
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Table 1: A  descriptive  statistics  of  clinical  and  laboratory  findings  in  the  study  
groups: 
            GROUP     
                                
 
VARIABLES       
COPD  WITH  
METABOLIC  
SYNDROME  
COPD  WITHOUT  
METABOLIC  
SYNDROME 
CONTROLS  
WITH  
METABOLIC  
SYNDROME 
CONTROLS  
WITHOUT  
METABOLIC  
SYNDROME 
P  VALUE 
AGE 61.9(S.D 7.9) 62.29( S.D 5.3) 65  (S.D 5.0) 62.6 (S.D 5.3) 0.676 
SEX M(28),F(14) M(28), F (14) M(3), F(4) M(26),F(9) - 
FEV1 1.90(S.D 0.60) 1.83(S.D 0.47) 3.80(0.27) 3.85(S.D 0.24) 0.001 
%FEV1 49.9(S.D 18.2) 51.36(S.D 15.2) 80.71(S.D 6.84) 81.31(S.D 4.06) 0.002 
WAIST 
CIRCUMFERENCE 
37.38(S.D 3.82) 34.00(S.D 1.73) 36.00(S.D 2.64) 34.74(S.D 1.63) 0.001 
BMI 26.12(S.D 4.87) 23.76(S.D 1.33) 24.06(S.D 0.70) 24.13(S.D 1.54) 0.003 
SBP 149.9(S.D 12.36) 133.86(S.D 
13.43) 
139.71(S.D 0.75) 125.25(S.D 9.25) 0.001 
DBP 85.81(S.D 7.18) 82.00(S.D 6.46) 90.00(S.D 0.01) 78.69(S.D 4.39) 0.002 
FBS 165.69(S.D 22.2) 127.57( S.D 
18.33) 
156.14(S.D 1.14) 124.71(S.D 
20.08) 
0.000 
TGL 171.71(S.D 14.9) 146.24(S.D 15.8) 162.00(S.D 8.5) 140.17(S.D 9.7) 0.001 
HDL – C 37.17(S.D 4.3) 46.12 (S.D 3.9) 40.57(S.D 3.10) 45.2(S.D 2.95) 0.002 
ESR 36.71(S.D 10.1) 28.17(S.D 6.5) 26.29(S.D 4.7) 22.97( S.D 3.5) 0.002 
CIMT 1.008(S.D 0.22) 0.826(S.D 0.16) 0.729(0S.D 0.05) 0.661(S.D 0.06) 0.001 
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AGE:  
Average  age  among  the  cases,  control 1  and  control 2  were  61.9, 62.29 and 65.  
There was  not  much  statistical  difference  in  age  among  the  different   groups   
Studied. 
 
FEV1:  
COPD  with  metabolic  syndrome  had  an  average  FEV1  of  1.90L, COPD   
Without   metabolic   syndrome   had   an   average   FEV1   of   1.83L  and   controls    
had  an  average  FEV1  of  3.82L. There  was  a  statistically   significant  difference  in   
FEV1 among  the  different  groups  studied. 
 
% FEV1  predicted: 
COPD  with  metabolic  syndrome  had  an  average  FEV1  predicted  of  49.9%,  
COPD  without  metabolic  syndrome  had  an  average  FEV1  predicted  of     
51.36%  and  controls  had  an  average  FEV1  predicted  of  81.36. There  was  a   
Significant  difference  in  % FEV1  predicted  among  the  different  groups  studied.   
 
WAIST  CIRCUMFERENCE: 
COPD  with  metabolic  syndrome  had  an  average  of   37.28  inches, COPD  without   
metabolic  syndrome  had  an  average  of  34  inches   and  controls  had  an  average  of  
35.37 inches. There  was  a  significant  difference  in  waist  circumference  among  the   
Different  groups  studied.    
 
BMI: 
COPD  with  metabolic  syndrome  had  an  average  of  26.12, COPD  without   
Metabolic   syndrome   had  an  average  of  23.76  and  controls  had  an  average  of   
24.09. There  was  a  significant  difference  in  BMI  among  the   groups   studied. 
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SYSTOLIC  BLOOD PRESSURE:    
Average  systolic blood pressure  in  COPD  with  metabolic  syndrome  was  149.9, in   
COPD  without  metabolic  syndrome  was 133.86, in controls  with  metabolic   
syndrome  was  139.71 and  in  controls  without  metabolic  syndrome was  125.25. 
There  was  a  significant  difference  in  systolic  blood  pressure  among  the  groups   
studied.  
 
DIASTOLIC  BLOOD  PRESSURE: 
Average  diastolic  blood  pressure  in  COPD  with  metabolic  syndrome  was  85.81, in   
COPD  without  metabolic  syndrome  was  82, in  controls  with  metabolic  syndrome   
Was  90.00  and  in  controls  without  metabolic  syndrome  was  78.69. There  was  a   
Significant   a  difference  in  diastolic  blood  pressure  among  the  groups  studied. 
 
FASTING  BLOOD  GLUCOSE: 
Average  fasting  blood  sugar  in  COPD  with  metabolic  syndrome  was  165.69 , in   
COPD  without  metabolic  syndrome  was  127.57, in  controls  with  metabolic   
syndrome  was  156.14 and  in  controls  without  metabolic  syndrome  was  
124.71.There  was  a  significant  difference  in  fasting  blood  glucose  level  among  the   
Groups  studied. 
 
TRIGLYCERIDES: 
Average  triglyceride  level  in  COPD  with  metabolic  syndrome  was  171.79, in   
COPD  without  metabolic  syndrome  was  146.24, in  controls  with  metabolic   
syndrome  was  162 and  in  controls  without  metabolic  syndrome  was  140.17.There   
was  a  significant  difference  in  triglycerides  level  among  the  groups  studied.                  
 
HDL-C: 
Average  HDL-C  level  in  COPD  with  metabolic  syndrome  was  37.17, in  COPD   
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Without  metabolic  syndrome  was  46.12, in controls  with  metabolic  syndrome  was  
40.57  and  in  controls  without  metabolic  syndrome  was  45.2. There  was  a   
Significant  difference  in  HDL-C  level  among  the  groups  studied. 
 
ESR: 
Average  ESR  in  COPD  with  metabolic  syndrome  was  36.71, in  COPD  without   
metabolic   syndrome  was  28.17, in  controls  with   metabolic  syndrome  was  26.29 
and  in  controls  without   metabolic  syndrome  was  22.97. There  was  a  significant   
difference  in  ESR  among  the  groups  studied. 
 
CAROTID  INTIMA  MEDIA  THICKNESS: 
 Figure 2: CAROTID  INTIMA  MEDIA  THICKNESS  IN DIFFERENT  GROUPS 
 
Average  CIMT  in  COPD  with  metabolic  syndrome  was  1.008, in COPD  without   
metabolic  syndrome  was  0.826, in  controls  with  metabolic  syndrome  was  0.729 
and  in  controls  without  metabolic  syndrome  was  0.661. There  was  a significant   
difference  in  CIMT  among  the  groups  studied.  
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SMOKING  STATUS  AMONG  DIFFERENT  GROUPS: 
 
                                               Figure 3: SMOKING  STATUS  AMONG  DIFFERENT  GROUPS 
 
In  COPD  with  metabolic  syndrome  , 23.8% were current  smokers, 31%  were  Ex   
smokers  and  45.20%  were  Non  smokers. In  COPD  without  metabolic  syndrome ,  
26.2%  were  current  smokers, 31%  were  Ex  smokers and  42.90%  were  non   
smokers. 
 
In controls  with  metabolic  syndrome, 14.30%  were  current  smokers,  
28.60%  were  Ex smokers and  57.10%  were  non  smokers.  In  controls  without   
metabolic syndrome ,  17.1%  were  current  smokers, 22.9%  were  ex  smokers  and   
60%  were non  smokers. . 
 
There  was  no  statistical  difference  in  smoking  status  among  the  groups  Studied. 
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TABLE 2:  Carotid  Intima Media Thickness  among  the  different  groups  : 
 
                                                                 
In  COPD  with  metabolic  syndrome  , 76.2%  had  elevated  CIMT, in  COPD  without   
Metabolic   syndrome  54.8%  had  elevated  CIMT, in  Controls  with  metabolic   
Syndrome  85.7%  had  elevated  CIMT  and  in  controls  without  metabolic  syndrome  
11.4%  had  elevated  CIMT. 
 
There  was  a  significant  increase  in  Carotid  intima  media  thickness  in  COPD   with   
metabolic  syndrome and  controls  with  metabolic  syndrome  with  p value  of  <   
0.021. 
  
   GROUPS 
TOTAL 
 
     
 
 
P  
VALUE 
   
COPD  WITH 
METABOLIC 
SYNDROME 
COPD 
WITHOUT 
METABOLIC 
SYNDROME 
CONTROLS 
WITH 
METABOLIC 
SYNDROME 
CONTROLS 
WITHOUT 
METABOLIC 
SYNDROME 
CIMT ELEVATED Count 32 23 6 4 65  
 
 
 
0.021 
% 
within 
GROU
P 
76.2% 54.8% 85.7% 11.4% 51.6% 
NORMAL Count 10 19 1 31 61 
% 
within 
GROU
P 
23.8% 45.2% 14.3% 88.6% 48.4% 
Total Count 42 42 7 35 126 
% 
within 
GROU
P 
100.0% 100.0% 100.0% 100.0% 100.0% 
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TABLE  3: Prevalance  of  carotid  plaque  among   different  groups : 
 
 COPD  WITH  
METABOLIC  
SYNDROME 
COPD 
WITHOUT 
METABOLIC 
SYNDROME 
CONTROLS 
WITH 
METABOLIC 
SYNDROME 
CONTROLS 
WITHOUT 
METABOLIC 
SYNDROME 
 
   P  VALUE 
CAROTID  
PLAQUE  
PRESENT 
   12 
28.6% 
     3 
7.1% 
0 0  
 
0.001 
CAROTID 
PLAQUE  
ABSENT 
30 
71.4% 
39 
92.7% 
7 
100% 
35 
100% 
 
                                                      
Among  COPD  patients   with  metabolic  syndrome,  28.6%  had  carotid  plaque. In  
 
COPD patients  without  metabolic  syndrome  , 7.1%  had  carotid  plaque. None  had   
 
Carotid  plaque  in  control group. There  was  significant  increase  in  carotid  plaque   
 
formation  in  COPD  patients  with  metabolic  syndrome (p<0.001)  
 
TABLE 4 : Carotid  Intima  Media  Thickness  vs  Carotid  Plaque  in  Cases  and   
Control 1: 
 
GROUP CAROTID  PLAGUE                            CIMT P  VALUE(CHI 
SQUARE TEST) ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
YES 12(37.5%) 0  
0.022 
NO 20(62.5%) 10(100%) 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
YES 3(13%) 6(31.6%)  
0.102 
NO 20(87%) 13(68.4%) 
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In  COPD  with  metabolic  syndrome , 37.5%  had  elevated  CIMT  with  carotid   
 
plaque. In  COPD  without  metabolic  syndrome 13.5%  had  elevated  CIMT  with   
 
carotid  plaque. There  was  significantly  elevated   CIMT   and   Carotid  plaque   
 
formation   in  COPD  patients  with  metabolic  syndrome(p< 0.022). 
 
 
 
TABLE 5:  MULTIPLE  REGRESSION  MODEL  FOR  VARIOUS  
CONFOUNDERS ASSOCIATED  WITH  CAROTID  INTIMA  MEDIA  
THICKNESS: 
 
CIMT: DEPENDANT  variable 
Model Unstandardized 
Coefficients 
Standardiz
ed 
Coefficient
s 
t Sig. 
B Std. Error Beta 
1 (Constant) 1.060 .669  1.584 .119 
AGE -.005 .003 -.154 -1.584 .119 
PACK YEARS .011 .004 .342 2.998 .004 
WAIST 
CIRCUMFERENC
E 
.003 .008 .039 .430 .669 
FBS .001 .001 .129 1.237 .222 
SBP .001 .002 .044 .369 .714 
DBP -.005 .003 -.155 -1.405 .166 
TGL .002 .001 .180 1.528 .132 
HDL-C -.004 .007 -.073 -.523 .603 
%FEV1 -.005 .001 -.440 -4.228 .000 
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By  keeping  CIMT  as  a  dependant  variable, all the  potential  confounding   factors  
are  plotted  against  CIMT. This  multiple  regression  analysis  was  done  to  determine  
whether  COPD  is  a  independent  risk  factor  for  increased  CIMT.   
By  using  multiple  regression  analysis  model  for  age, pack years, waist   
circumference,FBS, SBP,DBP,TGL,HDL_C and  % FEV1 predicted, with  CIMT  as  a   
dependant   variable, % FEV1  PREDICTED  and  SMOKING  PACK  YEARS   
were  Statistically  significant  independent  risk  factors  for  increased   CIMT. 
Thus  % fev1  predicted  and  smoking  pack  years  can  independently  influence  the  
carotid  intima  media thickness  irrespective  of  age and  individual  components  of  
metabolic  syndrome. 
 
TABLE  6: Correlation  of  CIMT  with  %FEV1  predicted: 
 
 CIMT 
(MEAN) 
%FEV1 
(MEAN) 
PEARSON  
CORRELATION 
SIGNIFICANCE (2 
TAILED) 
TOTAL(126) 0.841 60.83 - 0.688 0.000 
COPD(84) 0.917 50.63 -0.591 0.000 
COPD  WITH  
METABOLIC  
SYNDROME 
1.008 49.90 -0.725 0.000 
COPD  WITHOUT 
METABOLIC  
SYNDROME 
0.826 51.36 -0.480 0.001 
 
There  was  statistically  significant  negative  correlation  between  the  Carotid  Intima 
Media  thickness  and  % FEV1  predicted  among   the  126  study  subjects, and  among  
the  COPD patients  with  and  without  metabolic  syndrome.           
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TABLE 7:  Carotid  Intima  Media  Thickness  among  the  different  stages  of  
COPD: 
 
 CIMT (MEAN  +-2  S.D) P   VALUE ( ANOVA TEST) 
STAGE  1: 0.723( S.D 0.178)  
         0.004 
STAGE  2: 0.847(S.D 0.169) 
STAGE 3: 0.959(S.D 0.219) 
STAGE 4: 0.998(S.D 0.220) 
 
Average  CIMT  in  stage1, stage 2 , stage 3 and  stage 4 were  0.723, 0.847, 0.959  and  
0.998  respectively. There  was  a  significant  increase  in  CIMT  along  with  the  
increase  in  stages  of  COPD(p<0.004). 
 
TABLE 8:Association   of  Carotid  Intima  Media  Thickness  with  BODE  index  
in  cases  and  control 1: 
 CIMT ( MEAN +-2 SD) P VALUE ( ANOVA TEST) 
BODE: 0-2     0.735( S.D 0.15)  
0.002 
BODE: 3-4    0.836 ( S.D 0.17) 
BODE:5-6    0.925(S.D  0.20) 
BODE:>=7    1.048(S.D 0.20) 
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Average  CIMT  in  BODE index  0-2, 3-4, 5-6  and  >=7   were  0.735,  0.836, 0.925   
and 1.048  respectively. There  was  a  statistically  significant  increase  in  CIMT  along   
the  increase  in  BODE  index   among   COPD   patients. 
 
 
TABLE 9: Association  of  Carotid  Intima  Media  Thickness  with  six  minute  
walking  distance  in  cases  and  control 1: 
 
 CIMT ( MEAN +- 2 SD) P VALUE( ANOVA TEST) 
6MWD:>=350 0.703 (S.D 0.135)   
   0.003 
6MWD:250-349 0.814 (S.D 0.174) 
6MWD:150-249 0.984(S.D 0.184) 
6MWD:< 150 1.079(S.D 0.300) 
 
Average  CIMT  among  6MWD  of  >=350m, 250-349m, 150-249m  and  < 150m   in  
COPD  patients  were  0.703, 0.814, 0.984  and  1.079  respectively. There  was  a     
statistically  significant  increase  in  CIMT  along  the  decrease  in  6MWD  in  COPD   
patients.(p<0.003)             
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TABLE 10:  Carotid  Intima  Media  Thicknes  vs  Smoking  status: 
 
 CIMT ( MEAN +-2 SD) P VALUE  ( t TEST FOR EQUALITY 
OF MEANS) 
SMOKER 0.866(S.D 0.220)              0.483 
NON SMOKER 0.834(S.D 0.217) 
 
Average  CIMT  among  smokers  was 0.866  and  among  non  smokers  was  0.834. 
There  was  statistically  no  significant  difference  in  CIMT  among  smokers  and  non  
smokers. 
 
TABLE 11: carotid  intima  media  thickness  vs  biomass  exposure: 
 
GROUP BIOMASS  
EXPOSURE 
                           CIMT P  VALUE(CHI 
SQUARE TEST) 
ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
YES 15(46.9) 3(30%  
0.347 
NO 17(53.1%) 7(70%) 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
YES 10(43.5%) 6(31.6%)  
0.429 
NO 13(56.5%) 13(68.4%) 
 
            In  COPD  with  metabolic  syndrome, 46.9% with elevated  CIMT  had biomass   
            exposure. In COPD  without  metabolic  syndrome , 43.5%  with  elevated  CIMT  had   
            biomass  exposure. There  was  statistically  no  significant  difference  in  CIMT  with   
            respect  to  BIOMASS  exposure  among  the  two  groups.  
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            TABLE 12: Carotid  Intima Media Thickness  vs  MMRC DYSPNEA  SCALE: 
 
            GROUP MMRC                            CIMT P  VALUE(CHI 
SQUARE TEST) 
ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
< 2 5 ( 15.6%) 4(40%) 0.101 
>=2 27(84.4%) 6(60%) 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
<2 5(21.7%) 4(21.1%) 0.957 
>=2 18(78.3%) 15(78.9%) 
 
            In COPD  with  metabolic  syndrome , 84.4%  with  elevated   CIMT  had  MMRC >=2. 
In COPD  without  metabolic  syndrome , 78.3%  with  elevated  CIMT  had  MMRC 
>=2.There  was  statistically   no  significant  increase  in  CIMT  with  respect  to  MMRC  
dyspnea  scale  in both  the  groups. 
 
           TABLE 13:    Carotid  Intima  Media  Thickness  vs  No. Of  hospitalization: 
GROUP NO.OF 
HOSPITALISATION 
                           CIMT P  VALUE(CHI 
SQUARE TEST) 
ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
NIL 10(31.3%) 9(90%) 0.001 
>=1 22(68.7%) 1(10%) 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
NIL 14(60.9%) 12(63.2%) 0.879 
>=1 9(39.1%) 7(36.8%) 
 
           In  COPD  with   metabolic   syndrome,  68.7%   with   elevated   CIMT   had   increased 
           number  Of  hospitalization  and  it  was  found  to  be  statistically  significant (p<0.001). 
           In  COPD  without  metabolic  syndrome, 39.1%  with  elevated  CIMT  had  increased 
           number  of  hospitalization and it was  not  found  to  be  statistically  significant.   
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          TABLE 14:Carotid  Intima  Media  Thickness  Vs  number  of  exacerbations: 
      GROUP NO.OF   
EXACERBATIONS 
                           CIMT P  VALUE(CHI 
SQUARE TEST) ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
<2 14(43.8%) 9(90%)  
0.010 
>=2 18(56.3%) 1(10%) 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
<2 21(91.3%) 19(100%)  
0.188 
>=2 2(8.7%) 0 
 
            In  COPD  with  metabolic  syndrome, 56.3%  with  elevated  CIMT  were  frequent   
            exacerbators  and  it  was  found  to   be  statistically  significant(p<0.010). In  COPD   
            without  metabolic  syndrome , only  8.7%  with  elevated  CIMT  were  frequent   
            exacerbators  and  it  was  not  statistically  significant. 
 
           TABLE  15:  Carotid  Intima  Media  Thickness  vs  CAT  score: 
 
          GROUP CAT  SCORE                            CIMT P  VALUE(CHI 
SQUARE TEST) 
ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
<10 5(15.6%) 3(30%)  
0.312 
>=10 27(84.4%) 7(70%) 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
<10 4(17.4%) 3(15.8%)  
0.890 
>=10 19(82.6%) 16(84.2%) 
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 In  COPD  with  metabolic  syndrome, 84.4%  with  elevated  CIMT   had  CAT   
 score>=10. In  COPD  without  metabolic  syndrome, 82.6%  with  elevated  CIMT  had   
 CAT  score  >=10.There  was  no  statistically  significant  increase  in  CIMT  with   
  respect  to  CAT  score.   
           
 
           TABLE  16:  Carotid  Intima  Media  Thickness  vs  GOLD  COPD  CATEGORY:        
GROUP COPD  CATEGORY                            CIMT P  VALUE(CHI 
SQUARE TEST) 
ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
A 2(6.3%) 2(20%)  
0.064 
B 6(18.8%) 5(50%) 
C 3(9.4%) 1(10%) 
D 21(65.6%) 2(20%) 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
A 2(8.7%) 2(10.5%)  
0.751 
B 12(52.2%) 10(52.6%) 
C 5(21.7%) 2(10.5%) 
D 4(17.4%) 5(26.3%) 
 
  There  was  statistically  no  significant  increase  in  CIMT   with  respect  to  GOLD   
  COPD  CATEGORY  in  both  the  groups. 
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TABLE 17:Carotid  intima  media  thickness  vs  ESR: 
GROUP ESR                            CIMT P  VALUE(CHI 
SQUARE TEST) 
ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
ELEVATED 31(96.9%) 5(50%)  
0.001 
NORMAL 1(3.1%) 5(50%) 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
ELEVATED 10(43.5%) 8(42.1%)  
0.929 
NORMAL 13(56.5%) 11(57.9%) 
 
In COPD  with  metabolic  syndrome , 96.9%  with  elevated  CIMT  had  elevated  ESR 
and  it  was  found  to  be  statistically  significant.(p<0.001). In  COPD  without  
metabolic  syndrome , 43.5%  with  elevated  CIMT  had  elevated  ESR  and  it  was  not  
statistically  significant. 
TABLE 18:Carotid  intima  media  thickness  vs  Pao2: 
GROUP PAO2                            CIMT P  VALUE(CHI 
SQUARE TEST) 
ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
>80 1(3.1%) 9(90%)  
0.001 
60-80 27(84.4%) 1(10%) 
<60 4(12.5%) 0 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
>80 1(4.3%) 4(21.1%)  
0.178 
60-80 21(91.3%) 15(78.9%) 
<60 1(4.3%) 0 
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In  COPD  with  metabolic  syndrome, there  was  a stastically  Significant  increase  in   
CIMT  with  decrease  in  Pao2(p<0.001).  In  COPD  without  metabolic  syndrome  , 
there  was  no  statistically  significant   increase  in  CIMT  with  respect  to  Pao2.      
 
TABLE 19:  Carotid  Intima  Media  Thickness  vs  Paco2: 
 
GROUP PACO2                            CIMT P  VALUE(CHI 
SQUARE TEST) ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
<45 2(6.2%) 6(60%)  
0.001 
45-55 22(68.8%) 4(40%) 
>55 8(25%) 0 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
<45 4(17.4%) 3(15.8%)  
0.890 
45-55 19(82.6%) 16(84.2%) 
>55 0 0 
In  COPD  with  metabolic  syndrome  , there  was  a  statistically  significant  increase  in  
CIMT with  increase  in  Paco2(p<0.001). In  COPD  without  metabolic  syndrome,  
there  was  no  statistically  significant  increase  in  CIMT  with  increase  in  Paco2. 
TABLE  20:  Carotid Intima  media  thickness  vs  Pulmonary  hypertension: 
GROUP PHT                            CIMT P  VALUE( 
PEARSON CHI 
SQUARE TEST) 
ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
NO 0 1(10%  
0.208 
MILD 8(25%) 2(20%) 
MODERATE 16(50%) 3(30%) 
SEVERE 8(25%) 4(40%) 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
NO 6(26.1%) 6(31.6%)  
0.915 
MILD 8(34.8%) 5(26.3%) 
MODERATE 6(26.1%) 6(31.6%) 
SEVERE 3(13%) 2(10.5%) 
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There  was  no  statistically  significant  increase  in  CIMT  with  respect  to  pulmonary  
hypertension  in  both  the  groups. 
 
TABLE  21:  Carotid  Intima  Media  Thickness  vs  Right  ventricular  dysfunction: 
 
GROUP RIGHT  VENTRICLE  
DYSFUNCTION 
                           CIMT P  VALUE(CHI 
SQUARE TEST) 
ELEVATED NORMAL 
COPD  WITH  
METABOLIC  
SYNDROME 
YES 16(50%) 1(10%  
0.024 
NO 16(50%) 9(90%) 
COPD  WITHOUT  
METABOLIC  
SYNDROME 
YES 6(26.1%) 2(10.5%)  
0.201 
NO 17(74.9%) 17(89.5%) 
 
 
In  COPD  with  metabolic  syndrome  ,  50%  with  elevated  CIMT  had  right   
ventricular  dysfunction  and  it  was  found  to  be  statistically  significant(p<0.024). 
In  COPD  without  metabolic  syndrome ,  26.1%  with  elevated  CIMT  had  right   
Ventricular  dysfunction  and  it  was  not  statistically  significant. 
 
TABLE  22:Comparison  of  Clinical  Characteristics  in  COPD  with  metabolic  
syndrome  and  COPD  without  metabolic  syndrome  groups: 
 
MMRC  Dyspnea  scale, CAT score , Number  of  exacerbations,  Number  of  
hospitalizations and  Inhaled   corticosteroid  usage  were  compared  between  COPD 
with  and  without  metabolic  syndrome. 
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                                      GROUPS   P   VALUE 
COPD   WITH  
METABOLIC  
SYNDROME  
COPD  
WITHOUT  
METABOLIC  
SYNDROME 
MMRC  <2 9(21.4%) 9(21.4%) 1.000 
>= 2 33(78.6%) 33(21.4%) 
NO.OF  
HOSPITALISATIONS 
0 19(45.2%) 26(61.9%) 0.126 
>=1 23(54.8%) 16(38.1%) 
NO.OF  
EXACERBATIONS 
<2 23(54.8%) 40(95.2%) 0.001 
>=2 19(45.2%) 2((4.8%) 
CAT  SCORE <10 8(19%) 7(16.7%) 0.776 
>=10 34(81%) 35(83.3%) 
 INHALED  
CORTICOSTEROID 
USAGE 
YES 19(45.2%) 26(61.9%) 0.126 
NO 23(54.8%) 16(38.1%) 
 
In  COPD  with  metabolic  syndrome , 78.6%  had  MMRC  dyspnea  scale  >=2. In   
COPD  without  metabolic  syndrome , 21.4%  had  MMRC  dyspnea  scale  >=2. There    
was  no  statistically  significant  difference  in  MMRC  dyspnea  scale  between the  two   
groups.   
In  COPD  with  metabolic  syndrome,  54.8%   had   increased   number   of   
hospitalizations.  In  COPD  without  metabolic  syndrome, 38.1%  had  increased   
number  of  hospitalizations. There  was  no  statistically  significant  difference  in   
number  of  hospitalizations  in  between the two  groups.   
In  COPD  with  metabolic  syndrome, 45.2%  had  increased  number  of  exacerbations.  
in  COPD  without  metabolic  syndrome, 4.8%  had  increased  number  of   
exacerbations.There  was  a  statistically  significant  increase  in number  of     
exacerbations   in   COPD   with   metabolic   syndrome(p<0.001). 
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In  COPD  with  metabolic  syndrome , 81%   had  CAT  score   >=10. In  COPD  without   
metabolic  syndrome,  83.3%  had  CAT  score  >=10 . There  was  no  statistically   
significant  difference  in  CAT  score  among   the  two  groups. 
In  COPD  with  metabolic  syndrome, 45.2%  had  prior  Inhaled  corticosteroid  usage.In   
COPD  without  metabolic  syndrome, 61.9%  had  inhaled  corticosteroid  usage. There   
was  no  significant  difference  in  inhaled  corticosteroid  usage   among   the  two   
groups. 
There   was  a  statistically  significant  increase  in  number  of  exacerbations  in  COPD  
with  metabolic  syndrome group  and thus  they  are  frequent  exacerbators. 
 
GOLD  STAGING   AMONG  COPD  WITH  AND  WITHOUT  METABOLIC 
SYNDROME  GROUPS: 
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                       Figure 4: GOLD  STAGING  IN COPD  WITH  AND  WITHOUT  METABOLIC  SYNDROME GROUPS 
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In  COPD  with  metabolic  syndrome , 54.8%  and  31%  of  patients   were  in  stage  3  
and  stage 4. In  COPD   without   metabolic   syndrome,  33.3%   and  11.9%  of  patients  
were  in  stage  3  and  stage 4. There  was  statistically  significant  more  number  of  
patients   in  advanced  stages (stage 3 and stage 4)  in  COPD  with  metabolic  syndrome  
group.(p<0.01)  
    
GOLD  CATEGORY   AMONG  COPD  WITH  AND  WITHOUT   
METABOLIC  SYNDROME  GROUPS: 
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            Figure 5: GOLD  CATEGORY  AMONG  COPD WITH  AND  WITHOUT  METABOLIC  SYNDROME 
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In  COPD  with  metabolic  syndrome, 54.8%  of  the  patients  were  in  CATEGORY D 
, whereas  in  COPD  without  metabolic  ,52.4%  of  the  patients  were  in  CATEGORY  
B. There  was  a  statistically  significant  difference  in   GOLD   category   among   
these   two   groups.(p<0.014) . 
 
TABLE  23:  DISTRIBUTION  OF  ESR, CIMT, Pao2  and   Paco2  AMONG  THE  
COPD  WITH AND  WITHOUT  METABOLIC  SYNDROME  GROUPS: 
 
                                      GROUPS   P   VALUE 
COPD   WITH  
METABOLIC  
SYNDROME  
COPD  WITHOUT  
METABOLIC  
SYNDROME 
ESR ELEVATED 36(85.7%) 18(42.9%) 0.001 
NORMAL 6(14.3%) 24(57.1%) 
CIMT ELEVATED 32(76.2%) 23(54.8%) 0.039 
NORMAL 10(23.8%) 19(45.2%) 
 
PAO2 
>80 10(23.8%) 5(11.9%) 0.107 
60-80 28(66.7%) 36(85.7%) 
<60 4(9.5%) 1(2.4%) 
 
PACO2 
<45 8(19%) 7(16.7%) 0.009 
45-55 26(61.9%) 35(83.3%) 
>55 8(19%) 0 
 
In  COPD  with  metabolic  syndrome , 85.7%  had  elevated  ESR. In  COPD  without  
metabolic  syndrome  , 42.9%  had  elevated  ESR. There  was  a  statistically  significant  
increase  in  ESR  in  COPD  with  metabolic  syndrome  group.(p<0.001). 
54 
 
In  COPD  with  metabolic  syndrome, 76.2%  had  elevated  CIMT. In  COPD  without  
metabolic  syndrome , 54.8%  had  elevated  CIMT. There  was  a statistically  significant  
increase  in  CIMT  in COPD with metabolic  syndrome  group(p<0.039). 
There  was  no  statistically  significant  difference  in  Pao2  among  the  two  groups. 
In  COPD  with  metabolic  syndrome ,  61.9%  had  Paco2=  45-55  and  19%  had  
Paco2 > 55  and  it  was  found  to  be  statistically  significant  when  compared  with  
COPD  without  metabolic  syndrome  group(p<0.009). 
SIX MINUTE WALKING DISTANCE   IN  COPD  WITH  AND  WITHOUT  
METABOLIC  SYNDROME  GROUPS:  
 
                  Figure 6: 6MWD  IN  COPD  WITH  AND  WITHOUT  METABOLIC  SYNDROME GROUPS 
Average  6MWD  in  COPD   with  metabolic  syndrome  group  was  231m, whereas 
average  6MWD  in  COPD  without  metabolic  syndrome  group  was  284m. COPD  
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with  metabolic  syndrome  group  had  significantly  decreased  6MWD  when compared  
with  COPD without  metabolic  syndrome  group.(p<0.01). 
BODE   INDEX   IN  COPD  WITH  AND  WITHOUT  METABOLIC  
SYNDROME  GROUPS: 
 
                    Figure 7: BODE  INDEX  IN  COPD  WITH  AND  WITHOUT  METABOLIC  SYNDROME 
  
In  COPD  with  metabolic  syndrome, 38.1%  had  BODE  index  of  5 to 6 and  47.5% 
had  BODE  index  >=7. In  COPD  without  metabolic  syndrome, 28.6%  had  BODE  
index  of  5 to  6  and  14.3%  had  BODE  index  >=7. There  was  a  statistically  
significant  difference  in  BODE  index  among  the  two  groups(p<0.001). 
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TABLE  24: CAROTID  PLAQUE  IN  COPD  WITH  AND  WITHOUT   
METABOLIC  SYNDROME: 
 
   
GROUP 
Total 
P VALUE 
   
COPD WITH 
METABOLIC 
SYNDROME 
COPD WITHOUT 
METABOLIC 
SYNDROME 
CAROTID PLAGUE YES Count 12 3 15 0.010 
% within GROUP 28.6% 7.1% 17.9% 
NO Count 30 39 69 
% within GROUP 71.4% 92.9% 82.1% 
Total Count 42 42 84 
% within GROUP 100.0% 100.0% 100.0%  
 
 
In  COPD  with  metabolic  syndrome, 28.6%  had  carotid  plaque  formation.  In  COPD  
without  metabolic  syndrome,  7.1%  had  carotid  plaque  formation. There  was  a  
statistically   significant   increased  carotid   plaque  formation  in  COPD  with  
metabolic  syndrome(p<0.010).    
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PULMONARY  HYPERTENSION  IN  COPD  WITH  AND  WITHOUT  
METABOLIC  SYNDROME  GROUPS: 
 
 
              Figure 8: PHT  IN  COPD  WITH  AND  WITHOUT  METABOLIC  SYNDROME  GROUPS 
 
In  COPD  with  metabolic  syndrome, 2.4%  had  no  PHT, 23.8%  had  mild  PHT, 
45.2%  had  moderate  PHT  and  28.6%  had  severe  PHT. In  COPD  without  
metabolic  syndrome, 28.6%  had  no  PHT, 31.7%  had  mild  PHT, 28.6%  had  
moderate  PHT  and  11.9%  had  severe  PHT. There  was  a  statistically  significant  
difference  in  PHT  among  the  two  groups(p<0.03). 
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RIGHT  VENTRICULAR  DYSFUNCTION  IN  COPD  WITH  AND  WITHOUT  
METABOLIC  SYNDROME:     
 
 
    Figure 9: RV  DYSFUNCTION  IN  COPD  WITH  AND  WITHOUT  METABOLIC  SYNDROME  GROUPS 
 
In  COPD  with  metabolic  syndrome , 40.5%  had  right  ventricular  dysfunction.  In  
COPD  without  metabolic  syndrome, 19%  had  right  ventricular  dysfunction. There  
was  a  statistically  significant  increase  in  right  ventricular  dysfunction  among  
COPD  with  metabolic  syndrome  group(p<0.032). 
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TABLE  25:  PREVALANCE  OF  HYPERGLYCEMIA  IN  DIFFERENT  GROUPS: 
 
 
 
Figure 10: PROPORTION  OF  CONTROLLED  AND  UNCONTROLLED  DIABETES  AMONG  THE  GROUPS 
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HYPERGLYCEMIA  IN  DIFFERENT  GROUPS 
   GROUP Total 
   COPD WITH 
METABOLIC 
SYNDROME 
COPD 
WITHOUT 
METABOLI
C 
SYNDROM
E 
CONTROLS 
WITH 
METABOLIC 
SYNDROME 
CONTROLS 
WITHOUT 
METABOLIC 
SYNDROME 
FBS HYPERGLYCE
MIA 
Count 37 15 7 10 69 
% within 
GROUP 
88.1% 35.7% 100.0% 28.6% 54.8% 
NORMAL Count 5 27 0 25 57 
% within 
GROUP 
11.9% 64.3% .0% 71.4% 45.2% 
Total Count 42 42 7 35 126 
% within 
GROUP 
100.0% 100.0% 100.0% 100.0% 100.0% 
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In  COPD  with  metabolic  syndrome, 37  patients  had  hyperglycemia. Among  them  
40.5%  had  controlled  diabetes   and  59.5%  had  uncontrolled  diabetes.   
 
 In  COPD  without  metabolic  syndrome,  15  patients  had  hyperglycemia. Among  
them, 33.3%   had  controlled  diabetes   and   66.7%  had  uncontrolled  diabetes.   
 
In  Controls  with  metabolic  syndrome, all  the  patients(7)  had  hyperglycemia. Among  
them, 71.4%   had  Controlled  diabetes   and  28.6%  had  uncontrolled  diabetes.     
 
 In  controls  without  metabolic  syndrome, 10  patients   had   hyperglycemia. Among  
them , 80%   had  controlled  diabetes  and  20%  had  uncontrolled  diabetes.  
 
There  was  a  statistically  significant  difference  in  the   proportion of  controlled  and  
uncontrolled  diabetes  among   the  groups  studied(p<0.041). 
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TABLE 26: PREVALANCE  OF  HYPERTENSION  IN  DIFFERENT  GROUPS: 
   GROUP Total 
   COPD WITH 
METABOLIC 
SYNDROME 
COPD 
WITHOUT 
METABOLIC 
SYNDROME 
CONTROLS 
WITH 
METABOLIC 
SYNDROME 
CONTROLS 
WITHOUT 
METABOLIC 
SYNDROME 
BP HYPERTENSIO
N 
Count 35 22 7 6 70 
% within 
GROUP 
83.3% 52.4% 100.0% 17.1% 55.6% 
NORMAL Count 7 20 0 29 56 
% within 
GROUP 
16.7% 47.6% .0% 82.9% 44.4% 
Total Count 42 42 7 35 126 
% within 
GROUP 
100.0% 100.0% 100.0% 100.0% 100.0% 
 
 
 
 
Figure 11: Proportion  of  Controlled  and  Uncontrolled  Hypertension  among  the  groups 
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In  COPD  with  metabolic  syndrome,  35  patients   had    systemic  hypertension . 
Among  them   71.4%  had  controlled  SHT  and  28.6%  had  uncontrolled  SHT. 
 
In  COPD  without  metabolic  syndrome,  22  patients  had  systemic  hypertension. 
Among  them, 68.18%  had  controlled  SHT  and  31.18%  had  uncontrolled  SHT. 
 
In  controls  with  metabolic  syndrome , 6  patients  had  systemic  hypertension. Among 
them   85.7%  had  controlled  SHT  and  14.3%  had  Uncontrolled  SHT. 
 
In  controls  without  metabolic  syndrome,   5 patients  had  systemic  hypertension. 
Among  them 83.3%  had  controlled  SHT  and  16.7%  had  uncontrolled  SHT. 
 
There  was  a  statistically  significant  difference  in  the  proportion  of   controlled  and  
uncontrolled  Systemic  hypertension  among  the  groups(p<0.037). 
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                                                             DISCUSSION: 
 
COPD  is  a  multicomponent  disease  with  inflammation  at  its  core  leading  to  
mortality. Reduced  forced  expiratory  volume  in  one  second (FEV1)  has  been  
independantly  associated   with  increased  risk  for  cardiovascular  diseases. Systemic  
inflammation , chronic  hypoxia  and  oxidative  stress  are  the  possible  mechanisms  
contributing  to  the  development  of  cardiovascular  diseases  in  COPD  patients.  
 
 In COPD  patients, Systemic  inflammation  leads  to   progression  of  atherosclerosis  
and  thus  increases  the  risk  of  coronary  artery  disease , stroke  and  peripheral  
vascular  diseases. The  prevalence  of  metabolic  syndrome in  COPD  patients  is  two  
times  elevated  when  compared  with  normal  population. Metabolic  syndrome  is  also  
strongly  associated   with   systemic  inflammation  and  metabolic  syndrome  can  
independently  leads  to  progression  of  atherosclerosis. 
 
Carotid  Intima  Media  Thickness  and  Carotid  plaque  are  the  proven  measures  to  
estimate  the  carotid   atherosclerosis   and   thereby  to  predict  the  risk  for  coronary  
artery   atherosclerosis  and  other  cardiovascular   diseases. 
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As  far  as  we  know ,there  are  very  few  studies  in  literature   to  establish  the  
association   between  COPD, metabolic  syndrome  and  subclinical  athrerosclerosis.  
 
Comorbidities  associated  with  COPD  is  an  area  of  research  and  systemic  
inflammation  being  a  most  common  etiology  for  the  associated  comorbidities, 
diagnosing  metabolic  syndrome  and  measuring  Carotid  intima  media  thickness in  
all  the  COPD  patients  may  help  us  to  predict  the  cardiovascular  diseases  in  
advance. 
So  the  purpose  of  this  study  was  to  evaluate  the  association   of  subclinical  
atherosclerosis  in  COPD  patients  with  metabolic  syndrome.       
 
AGE: There  was  no  statistically  significant  difference  in  age  among  the  groups. 
 
AIRFLOW LIMITATION: There was  a  statistically  significant  decrease  in  FEV1  
and  %  FEV1  predicted  in  COPD  patients  when  compared  with  controls.  COPD  
with  metabolic  syndrome  patients  had  significantly  lower  FEV1  and %  FEV1  
predicted  when  compared  with  COPD  without  metabolic  syndrome  patients. 
Minas  et al., (38) in  his  study  observed  that  COPD  patients  with  the  MetS  have  a  
more   
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severe  form  of  disease,  more  dyspnea,  a  lower  FEV1  and  require  more  
inhalational  glucocorticoids  to  control  the  disease. 
 
WAIST  CIRCUMFERENCE: COPD  patients  with  metabolic  syndrome  had  
statistically  significant  higher  waist  circumference  when  compared  with  other   
groups. 
BMI: There  was  a  statitiscally  significant  increase  in  BMI  in  COPD  with  
metabolic  syndrome  group. Even  in  COPD  with  metabolic  syndrome group, average  
BMI  was  only  26.12. This  may  be  because of  the  increased  prevalence  of   
abdominal  obesity  rather  than  the  increase  in  whole   body  mass  index  in  these  
patients. 
SYSTEMIC  HYPERTENSION: 
There  was  a  statistically  significant  increased  prevalence  of  systemic  hypertension  
in  COPD  with  metabolic  syndrome  group. Among  the  groups, COPD  with  
metabolic  syndrome  and  COPD  without  metabolic  syndrome  had  significantly  
higher  number  of  uncontrolled  hypertension(p<0.037). 
Wang y et al.,(43) explained  the  possible  mechanisms  for  this  increased  prevalence  
of  systemic  hypertension  in  COPD  as follows:  hypoxia  related  vasoconstriction , 
free radical injury,  endothelial  dysfunction   and arterial  stiffness. 
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DIABETES  MELLITUS: 
There  was  a  statistically  significant  increase  in  the  prevalence  of   diabetes  mellitus  
in  COPD  with  metabolic  syndrome  group. Among the  study  groups, COPD  patients  
had  significantly  higher  number  of  uncontrolled  diabetes  when  compared  with  
controls(p<0.041). 
 
The  nurses’  healthy  study(42)  a  prospective  study  over  an  8-year  period  had   
showed that  COPD  patients  have  a  1.8%   relative  risk  of  developing  diabetes. 
 
Engstrom et al.(50)  described  that  reduced  lung  function  is  an  important  risk  factor   
for the  development  of  diabetes  in  COPD.  
 
Skyba et al., explained that Adipose  tissue  inflammation  and  low  grade  systemic  
inflammation plays  an  important  role  in  whole  body  insulin  resistance  and   beta  
cell dysfunction   in   COPD  patients  and  thus  may   lead   to  the  increased  
prevalence  of  uncontrolled  diabetes(22) . 
 
ESR: There  was  a significant  increase  in  ESR  in  COPD  patients  with  metabolic  
syndrome .This  may  be  because  of  the  increased  systemic  inflammation  associated  
with  the  disease. 
CAROTID  INTIMA  MEDIA  THICKNESS: 
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In  our  study , average  CIMT  in  COPD  with  metabolic  syndrome  was  1.008, 
average  CIMT  in  COPD  without  metabolic  syndrome  was  0.826 , average  CIMT  in  
controls  with  metabolic  syndrome  was  0.729  and  average  CIMT  in  controls  
without  metabolic  syndrome  was  0.661. 76.2%  had  elevated  CIMT  in  COPD  
patients  with  metabolic  syndrome  and  54.8%   had   elevated   CIMT   in   COPD   
patients  without   metabolic  syndrome.   
There  was  a  significant  increase  in  CIMT  in  COPD   patients  when  compared  with  
controls.  Among  the  COPD  patients, COPD  with  metabolic  syndrome  had  higher  
CIMT  than  COPD  without  metabolic  syndrome.  Thus  COPD  patients  are  more  
atherogenic  when  compared  with  controls  and  among  the COPD  patients, those  
with  metabolic  syndrome  are  even  more  atherogenic  than  those  without  metabolic  
syndrome.  
 
Sandhip chindhi et al.,(57) in his  study  observed  that  Mean  average  CIMT  in  COPD 
patients was 1.07 ± 0.49 mm and in controls, it was 0.75 ± 0.33 mm. It was significantly 
higher in COPD patients than control (P = 0.000). In COPD patients, 67.6%  patients  
had  increased  average  CIMT  and  where  as  it  was  25.8%  in controls (P = 0.000).  
CIMT  was  further  increased in  COPD  patients  with  MetS. Mean  average  CIMT  in  
COPD  patients  with  MetS  was  1.22 ± 0.528 mm  while in  patients  without  MetS  
mean  average  CIMT  was  0.74 ± 0.086 mm (P < 0.000). 
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Aylin ozgen alapadin  et al.,(58) in his  study  observed  that  COPD group had a 
statistically significant  thicker  carotid  IM  compared  to  controls (p < 0.001). In COPD 
patients with MetS, IMT did not show a significant increase compared to COPD patients 
without MetS (1.11 ± 0.24 mm vs. 1.04 ± 0.26 mm; p = 0.34). Another important finding 
was that there was no significant difference between IMT values of participants with 
MetS and without MetS (1.01 ± 0.25 mm vs 0.95 ± 0.24 mm; p = 0.20). This  statement  is  
in  contrary  to  our  study  results  and  to  the   results  of  study  conducted  by  sandhip  
chindhi  et al.  Maybe  the  difference  in  study  population  and  methodology  could  
have  been  the  reason  for  this  disparity. 
 
CAROTID  PLAQUE: 
In our  study, there  was  a  significant  increase  in  carotid  plaque  formation  in  COPD  
patients  when  compared  with  controls. Among  the  COPD  patients  , those  with  
metabolic  syndrome  had  significantly  higher  carotid  plaque  formation  than  those  
without  metabolic  syndrome (28.6% vs 7.1%) (p<0.001). 
Sandhip  chindhi  et  al,(57) in  his  study  stated  that  in COPD  patients, carotid plaque 
was seen in 38.7% patients, whereas 13.7% of controls  had  carotid  plaque (P = 0.000). 
Carotid  plaque  was  seen  in  54.5%  patients of  COPD  with  MetS  and  in 2.3%  of  
COPD  patients  without  MetS (P < 0.000).  
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CAROTID  INTIMA  MEDIA  THICKNESS  AND  CAROTID  PLAQUE   
FORMATION: 
 
In  COPD  with  metabolic  syndrome , 37.5%  had  elevated  CIMT  with  carotid   
plaque. In  COPD  without  metabolic  syndrome 13.5%  had  elevated  CIMT  with   
carotid  plaque. There  was  significantly  elevated   CIMT   and   Carotid  plaque   
formation   in  COPD  patients  with  metabolic  syndrome(p< 0.022). 
 
In  a  study  by  Sandhip  chindhi et al.,(57) frequency of carotid plaque (38.7% vs. 
13.7%, P < 0.0001) and increased CIMT (67.6% vs. 25.8%) were significantly higher in 
COPD patients compared to age- and sex-matched controls 
The Rotterdam study(56) also revealed a significantly higher CIMT (≥2.5 mm) in 
participants with COPD than in those without COPD.           
   
CORRELATION  OF  CIMT  WITH  %FEV1  PREDICTED: 
In  our  study,  there  was  a  statistically  significant  negative  correlation  between  the  
CIMT  and  % FEV1  predicted. The  decrease  in  % FEV1  predicted  is  associated  
with  the  significant  increase  in  carotid  intima  media  thickness. 
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CORRELATION  OF  CIMT  WITH  SEVERITY  OF  AIRFLOW  LIMITATION: 
In  our  study, average  CIMT  in  stage1, stage 2 , stage 3 and  stage 4 were  0.723, 
0.847, 0.959  and 0.998  respectively. There   was  a   statistically   significant  increase  
in   CIMT  with  the  increase  in  severity  of  airflow  limitation(p<0.004). 
 
In  a  study  by  Sandhip  chindhi  et  al.,(57) the  mean  CIMT  showed an increasing 
trend with increased severity of COPD. The mean CIMT in GOLD stages I, II, III, IV 
COPD were 0.96 ± 0.32, 0.98 ± 0.52, 1.16 ± 0.47, 1.20 ± 0.59, respectively. Frequency of 
carotid plaque according to GOLD stages I, II, III, IV were 36.4%, 23.5%, 43.2%, and 
51.6%, respectively; a P value for changing trend was 0.115. 
 
In the study by Gestel et al.(55)  the  mean  carotid  wall  IMT  was  1.07 mm. Of the 
patients without COPD, 23% demonstrated increased CIMT, whereas 32% of patients 
with mild COPD and 36% of the patients with moderate/severe COPD had increased 
CIMT (P < 0.01). 
 
In  a  study  by  Aylin  ozgen  alappadi  et al.(58), there was no correlation between IMT 
and disease stage, FEV1%, or serum CRP level. When only smokers were considered, 
IMT was found to be higher in the COPD group compared to controls (p < 0.006). This 
finding might suggest that, although we could not demonstrate a direct correlation 
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between FEV1% and IMT, patients with airflow obstruction are  more  proneto 
atherogenesis due to some other mechanisms beyond smoking. 
 
SMOKING  STATUS  AND  CIMT: 
In our  study , 14  females  each  were  present  in  all the  three  groups(cases, control1 
and  control 2). Therefore  in  all  the  four  groups  , there  was  statistically  significant  
increase  in  proportion  of  non  smokers(45.2%, 42.9%,57.1%, 60%) . 
In  our  study, average  CIMT  among  smokers  were  0.866  and  average  CIMT  among  
non  smokers  were  0.834. There  was  statistically  no  significant  difference  in  CIMT  
with  respect  to  smoking  status. 
 
Iwamoto et al.,(54) reported a mean CIMT of significantly higher level in smokers with 
airflow limitation (0.78 mm) than that in smokers without airflow limitation (0.73 mm) 
(P < 0.01) and never-smokers (0.73 mm) (P < 0.005). Carotid plaque was significantly  
prevalent  in smokers with  airflow  limitation  (73.8%) than control never-smokers 
(48.4%; P < 0.005).  
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Sandhip  chindhi  et  al.,(57) reported  that  there  was  exaggerated  subclinical 
atherosclerosis  in  smokers  with  airflow  limitation,  indicating  that  atherosclerotic 
change  occurs  early  in  the  disease  process  of  COPD. The  shared  risk  factors such 
as smoking between COPD and carotid atherosclerosis can also explain the associations. 
However, they  did  not  find  a  significant relationship  between smoking  status  and  
increased  CIMT. 
ASSOCIATION  OF  CIMT  WITH  BODE  INDEX: 
In  our  study,  there  was  a  statistically  significant  increase  in   CIMT  with  the  
increase  in  BODE  index  in  cases  and  controls 1(p<0.002). 
BODE  index  being   a  multidimensional  marker  of  a  disease  taking  into  
consideration  the  systemic  nature  of  disease. It  helps  us  to  predict  the  4  year  
survival  prediction  rate  among  COPD  patients. Thus  in  our  study  , increased  
BODE  index  was  associated  with  increased   CIMT  and  thus  these  patients  are  
prone  for  atherosclerosis  and   increased  cardiovascular  diseases. 
 
ASSOCIATION  OF  CIMT  WITH  SIX  MINUTE  WALIKNG  DISTANCE: 
In  our  study ,  there  was  a  significant  increase  in  CIMT  with  the  decrease  in  
6MWD(p<0.003). 
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SIX  minute  walking  test  is  used  as  a  measure  to  predict  the   exercise  capacity  in  
COPD  patients .In our  study,  decrease  in   6MWD   is   associated   with  increase  in  
CIMT   and  the  possible  mechanism  could  be  the  decreased  physical  activity  
associated  with  decreased  exercise  capcity  and  thus  physical  inactivity  in  relation  
with  systemic  inflammation  may  predispose  these  COPD  patients   for  an  increased  
subclinical  atherosclerosis.         
CAROTID  INTIMA  MEDIA  THICKNESS  AND  BIOMASS  EXPOSURE: 
There  was  statistically  no  significant  difference  in  CIMT  with  respect  to  biomass  
exposure  in  our  study. 
Sandhip  chindhi  et al.,(57)  reported  that  There are no significant differences between 
COPD and control in terms of smoking status, biomass exposure, age, and sex. 
CAROTID   INTIMA  MEDIA  THICKNESS  AND  CLINICAL  
CHARACTERISTICS  OF  COPD: 
MMRC  DYSPNEA  SCALE:  
In  our  study, there  was   statistically  no   significant  difference in  CIMT  with  respect  
to  MMRC  dyspnea  scale. 
NUMBER  OF  HOSPITALISATIONS: 
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In  COPD  patients   with  metabolic  syndrome , there  was  a  significantly  increased  
CIMT  when  there  was  increased  number  of  hospitalizations(p<0.001). 
In  COPD  patients  without  metabolic  syndrome, number  of   hospitalizations  was  not  
significantly  associated  with  CIMT(p<0.879). 
Thus  COPD  patients   with  metabolic  syndrome   having    higher   rate  of  
hospitalisations    with  increased  CIMT  are  prone  for  increased  cardiovascular  
diseases. 
NUMBER  OF  EXACRBATIONS: 
In  COPD  patients  with  metabolic  syndrome, increased  number  of  exacerbations  was  
significantly  associated  with  increased  CIMT(p<0.010). 
In COPD  patients  without  metabolic  syndrome, there  was  no  significant  increase  in  
CIMT  with  respect  to  increased  number  of  exacerbations. 
Thus  COPD  patients  with  metabolic  syndrome  are  frequent  exacerbators  and  they  
are   more  prone  for  atherosclerosis. 
CAT  SCORE: 
In our  study , CAT  score  was  not  significantly  associated  with  CIMT  in  both  the  
groups.   
CAROTID  INTIMA  MEDIA  THICKNESS  AND  GOLD  CATEGORY: 
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There  was  no  significant  difference  in  CIMT  with  respect  to  GOLD  COPD  
category  in  our  study. 
CAROTID  INTIMA  MEDIA  THICKNESS  AND  ESR: 
In  our  study,  increased  CIMT  was  significantly  associated  with  the  elevated  ESR  
in  COPD  patients  with  metabolic  syndrome(p<0.001). 
 Alyin ozgen alappadi et al.,(58) reported  that  serum  CRP  levels  were  elevated  in  the 
study  participants  with  MetS (p = 0.02). 
 
CAROTID  INTIMA  MEDIA  THICKNESS  AND  ABG: 
In  COPD  patients  with  metabolic  syndrome, increased  CIMT  was  significantly  
associated  with  the  worsening  Pao2  and  Paco2(P<0.001,P<0.001). 
Both  hypoxia  and  hypercapnia  are associated  with increased  CIMT  and  thereby  
prone  for  cardiovascular  diseases. 
 
CAROTID  INTIMA  MEDIA  THICKNESS  AND  PHT: 
There  was  no   significant  difference  in   CIMT  with  respect  to  severity  of  PHT  in  
our  study. 
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CAROTID  INTIMA  MEDIA  THICKNESS  AND  RIGHT  VENTRICULAR  
DYSFUNCTION: 
In  COPD  patients  with  metabolic  syndrome  ,  increased  CIMT  was  significantly  
associated  with  right  ventricular  dysfunction(P<0.024). 
COPD  patients  with  metabolic  syndrome  are  more  prone  for  right ventricular  
dysfunction  due  to lipotoxic  cardiomyopathy. 
 
COPD  AS  A  INDEPENDENT  RISK  FACTOR  FOR  INCREASED  CIMT: 
By  multiple  logistic  regression  model, % FEV1  predicted  and  smoking  pack  years  
are  independent  risk  factors  for  increased  CIMT  in  our  study.(beta-0.440, P<0.000) 
In  a  study  by  Alyin  ozgen  alappadi   et al.,(58) A multivariate-adjusted analysis 
showed that in all the study population IMT had a positive correlation with COPD 
(beta = 0.151, p = 0.020). Among the potential confounding factors, age and BMI were 
also positively correlated with IMT (beta = 0.008, p = 0.020 and beta = 0.011, p = 0.029, 
respectively). Other factors (i.e. age, smoking, hypertension, FPG, triglyceride, HDL-
cholesterol) had no significant association with IMT. 
Sandhip  chindhi  et  al.,(57)  reported  that on linear regression analysis, MetS and 
COPD were the independent predictors of increased CIMT. Similarly on multinomial 
logistic regression analysis, COPD was found to be an independent predictor of carotid 
plaqing with regression coefficient of 0.847 (P < 0.023). Association between PO 2 , 
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PCO 2 and SPO 2 with carotid plaqing was not found to be statistically significant in 
correlation matrix. 
 
CLINICAL  AND  FUNCTIONAL  CHARACTERISTICS  IN  COPD  WITH  
METABOLIC  SYNDROME  AND  COPD  WITHOUT  METABOLIC  SYNDROME  
GROUPS: 
In  a  study  conducted  by  a  dukhabandhu  naik  et  al.,(29) COPD   patients  with  the 
MetS had a more severe form of disease, more dyspnea, a lower FEV1 and require more 
inhalational  glucocorticoids  to  control  the  disease. They  also  proposed  that  this 
group of COPD subjects can be further stratified into a higher risk phenotype which 
requires a closer follow-up. 
A recent study by Minas et al.(38) has shown that  MetS is also quite common among 
younger age group  and in even subjects with a less  severe form of COPD.   COPD 
patients with MetS have higher leptin levels,  low  adiponectin  and  greater  insulin  
resistance. 
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In our  study , there  was  statistically  no  significant  difference  in  MMRC  dyspnea  
scale, number  of  hospitalizations , CAT  score, inhaled  corticosteroid  usage  and  Pao2 
in  between  the  two  groups.  
COPD  patients  with  metabolic  syndrome  in   our   study  had  statistically  significant  
        1.Higher  number  of  exacerbations  and  thus  they  are  frequent  
exacerbators(P<0.001). 
        2.Increased  severity  of   airflow  limitation(p<0.01)  
        3.Increased  CIMT  and  thus  more  prone  for  cardiovascular  diseases(p<0.039) 
        4.Increased   CO2  retention(p<0.009) 
        5.Decreased   exercise  capacity(6MWD: Ave  231m  vs  284m). 
        6.Higher  BODE  index  and  therefore  they  have  lower  4  year  survival  
prediction   rate.(p<0.001) 
       7. Higher   carotid   plaque  formation(28.6% vs 7.1%) 
       8. Increased  severity  of  pulmonary  hypertension(P<0.03) 
       9. Increased  right  ventricular  dysfunction(p<0.032).           
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                                                      CONCLUSION:  
 
1. In  our  study,  COPD  patients  had  increased  Carotid  intima  media  thickness  and  
carotid  plaque  formation  when  compared  with  the  age  and  sex  matched  healthy  
controls. Thus  COPD  patients  are  at  increased  risk  for  atherosclerosis and  
cardiovascular  diseases. 
2. Increased   carotid   intima  media  thickness  was  associated  with  the  trend  of  
increasing   severity  of  airflow  limitation. Thus severe  and  very  severe  COPD  
patients  are  at  increased  risk  for  atherosclerosis   than  mild   and  moderate  COPD  
patients. 
3. COPD  patients  with  high  BODE  index  had  significantly  elevated   Carotid  intima  
media  thickness  and  thus  they  are  more  prone  for  cardiovascular  morbidity  and  
mortality. 
4. %FEV1  predicted  and  smoking  pack  years  were  the  independent  risk  factors  
associated   with  increased   carotid   intima   media   thickness  in  our  study. 
5. In our  study,  COPD  patients  with  metabolic  syndrome  had  increased  number  of  
exacerbations , increased  severity  of  airflow  limitation , poorer  exercise  tolerance , 
lower  4  year  survival  prediction rate,  increased  subclinical  atherosclerosis  and  
increased   right   ventricular   dysfunction.  Thus  COPD  patients  with  metabolic  
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syndrome  can  be  considered  as   high  risk  phenotype  with  worsened  COPD  
characteristics  and  they  are  more  prone  for  cardiovascular  diseases. 
6. In  COPD  patients  with  metabolic  syndrome, elevated  CIMT  was  significantly  
associated  with  increased  number  of  hospitalizations, increased  number  of  
exacerbations, decreased  six  minute  walking  distance, higher  BODE  index, 
worsening  Pao2  &  Paco2  and  right  ventricular  dysfunction. From  the  above  
mentioned  observations  it  is  clear  that  subclinical  atherosclerosis  is  strongly  
associated   with   worsened   COPD   characteristics. 
 
In  Summary, COPD  is  a  multicomponent  disease  with  inflammation  at  it’s  core  
leading   to  mortality. In  COPD  patients , prevalence of  metabolic  syndrome  is  more  
common  and  it  is  associated  with  worsened   clinical  and  functional  characteristics. 
Both  COPD  and  METABOLIC  SYNDROME  can  cause  progression  of  
atherosclerosis  and  are  associated  with  increased  cardiovascular  mortality.  
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RECOMMENDATIONS: 
CAROTID  INTIMA  MEDIA  THICKNESS  AND  CAROTID  PLAQUE  formation  
can   be  routinely  screened  in  all  the  COPD  patients. Thus  non-invasive  and cost  
effective  2D  carotid  Doppler  as  a  part  of  investigation  panel   for  cardiovascular 
disease  risk   prediction  can  help  us  to  decrease  the  cardiovascular  morbidity  and  
mortality   associated   with   COPD.             
 
LIMITATIONS OF  THE  STUDY: 
 
1. Being  a  hospital  based   case  control   study, extrapolating  the  results  of  the  
study  to  the  general  population  in  society  may  not  be accurate  enough  and  
further  studies  in  this  context  has  to  be  done  in  general  population. 
 
2. More  specific  inflammatory   biomarkers  like   CRP,  fibrinogen,  leptin   and  
IL-6 were  not  done  in  our  study. The  correlation   between  the   CIMT  and  
these   inflammatory  biomarkers  could  have  given  better  outcome  with  
respect  to  inflammatory  status  associated  with  the  COPD. 
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COPD- Chronic  obstructive  pulmonary  diseases 
METS- Metabolic  syndrome 
CAT -COPD  assessment  test 
MMRC- Modified medical  research council  
CIMT- Carotid  Intima Media  Thickness 
PHT- Pulmonary  hypertension 
RVD-  Right  ventricular  Dysfunction 
HDL- High  density  lipoprotein 
LDL- Low  density  lipoprotein 
TGL- Triglycerides 
ESR- Erythrocyte  sedimentation  rate 
FEV1- Forced expiratory  volume  in  one  second 
FVC- forced vital  capacity 
SHT- systemic  Pulmonary  Hypertension 
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AGE SEX mMRC 
NO OF 
HOSPITALI
SATION
NO OF 
EXACERBA
TIONS
CAT 
SCORE SMOKER
PACK 
YEARS
BIOMASS 
EXPOSURE RADIOLOGY FEV1 %FEV1 COPD
AIRFLOW 
LIMITATION 
SEVERITY
COPD 
CATEG
ORY
MET 
SYNDR
OME
WAIST 
CIRCUMF
ERENCE    BMI
63 M 3 2 3 21 CURRENT 35 NO EMPHYSEMA 1.65 43% YES SEVERE D YES 36 23.5
56 M 2 0 1 14 FORMER 20 NO BRONCHITIS 2.14 58% YES MODERATE B NO 37 23.8
63 M NA NA NA NA CURRENT 30 NO NORMAL 3.36 83% NO NO NA NO 35 23
56 F 2 1 2 15 NO 0 YES BRONCHITIS 1.86 52% YES MODERATE D YES 40 31.6
62 F 1 0 1 12 NO 0 YES BRONCHITIS 2.56 58% YES MODERATE B NO 33 22.6
56 F NA NA NA NA NO 0 YES NORMAL 3.47 84% NO NO NA NO 41 26
68 M 2 0 1 18 FORMER 15 YES BRONCHITIS 3.21 61% YES MODERATE B YES 37 23
63 M 3 2 4 26 CURRENT 40 NO EMPHYSEMA 1.36 36% YES SEVERE D NO 35 23
68 M NA NA NA NA NO 0 NO NORMAL 3.25 88% NO NO NA NO 37 24
50 F 2 0 1 14 NO 0 YES BRONCHITIS 3.21 67% YES MODERATE B YES 40 31.4
70 F 3 2 3 29 NO 0 YES EMPHYSEMA 1.26 29% YES VERY SEVERE D YES 42 33
59 F 1 0 0 8 NO 0 YES BRONCHITIS 3.36 83% YES MILD A YES 41 34
61 F 2 0 2 16 NO 0 YES BRONCHITIS 3.34 69% YES MODERATE D YES 42 31.2
56 F 3 1 3 22 NO 0 YES BRONCHITIS 2.43 45% YES SEVERE D YES 45 34.5
58 F 2 1 5 24 NO 0 NO EMPHYSEMA 2.14 40% YES SEVERE D YES 42 33
63 F 3 2 6 28 NO 0 YES EMPHYSEMA 1.33 27% YES VERY SEVERE D YES 43 30.5
67 F 1 1 2 7 NO 0 YES BRONCHITIS 1.78 52% YES MODERATE C YES 40 31.5
49 M 1 0 0 8 NO 0 NO BRONCHITIS 2.43 82% YES MILD A YES 45 33.2
72 M 2 0 1 17 FORMER 30 NO EMPHYSEMA 1.89 53% YES MODERATE B YES 44 34.5
54 M 3 1 4 24 CURRENT 28 NO EMPHYSEMA 1.56 46% YES SEVERE D YES 41 32.3
59 M 1 1 1 8 CURRENT 24 NO BRONCHITIS 1.48 48% YES SEVERE C YES 44 34.2
65 M 3 2 6 25 FORMER 40 NO EMPHYSEMA 1.28 29% YES VERY SEVERE D YES 41 33.5
63 M 1 0 0 8 NO 0 NO EMPHYSEMA 2.78 81% YES MILD A YES 34 23
52 M 2 0 1 18 NO 0 YES BRONCHITIS 2.32 67% YES MODERATE B YES 36 24.3
66 M 2 1 3 16 NO 0 NO BRONCHITIS 1.65 38% YES SEVERE D YES 38 22.6
58 M 3 2 5 24 NO 0 YES EMPHYSEMA 1.29 26% YES VERY SEVERE D YES 36 23.8
74 M 3 3 6 31 FORMER 44 NO EMPHYSEMA 1.16 28% YES VERY SEVERE D YES 33 20.3
76 M 3 4 7 27 FORMER 46 YES EMPHYSEMA 1.24 27% YES VERY SEVERE D YES 35 21.4
57 M 2 0 1 14 CURRENT 24 NO BRONCHITIS 1.36 26% YES VERY SEVERE B YES 34 22
49 M 2 0 2 18 CURRENT 18 NO EMPHYSEMA 1.78 43% YES SEVERE D YES 33 23.4
66 M 3 1 4 23 FORMER 26 YES EMPHYSEMA 1.57 38% YES SEVERE D YES 37 24.2
53 M 1 0 1 14 CURRENT 16 NO BRONCHITIS 2.26 58% YES MODERATE B YES 36 23.5
58 M 2 0 1 16 CURRENT 22 NO BRONCHITIS 2.14 53% YES MODERATE B YES 35 21.8
64 M 1 0 2 5 FORMER 26 NO EMPHYSEMA 1.87 59% YES MODERATE C YES 33 22.6
63 M 2 0 2 16 FORMER 25 NO EMPHYSEMA 2.34 80% YES MILD D YES 36 23.4
73 M 2 0 1 17 FORMER 26 NO BRONCHITIS 2.16 81% YES MILD B YES 37 24.2
78 M 2 0 1 21 FORMER 23 NO EMPHYSEMA 1.84 64% YES MODERATE B YES 38 23.1
68 M 2 0 0 18 CURRENT 16 YES EMPHYSEMA 2.18 82% YES MILD B YES 35 23.7
67 M 3 1 4 23 FORMER 25 NO EMPHYSEMA 1.67 45% YES SEVERE D YES 35 22.8
55 M 2 1 3 27 CURRENT 28 NO BRONCHITIS 1.78 42% YES SEVERE D YES 37 23.8
65 M 3 2 3 25 FORMER 35 NO EMPHYSEMA 1.16 25% YES VERY SEVERE D YES 33 23.5
68 M 1 2 4 7 FORMER 33 NO BRONCHITIS 1.56 43% YES SEVERE C YES 35 21.4
71 M 2 1 4 25 CURRENT 47 NO EMPHYSEMA 1.25 27% yes VERY SEVERE D YES 36 22.6
46 F 1 0 1 8 NO 0 YES BRONCHITIS 2.21 65% YES MODERATE A YES 33 23.4
51 F 2 1 2 16 NO 0 YES BRONCHITIS 1.65 46% YES SEVERE D YES 34 23.5
57 F 3 1 4 23 NO 0 YES EMPHYSEMA 1.46 42% YES SEVERE D YES 32 21.6
63 F 3 2 6 27 NO 0 YES EMPHYSEMA 1.14 28% YES VERY SEVERE D YES 34 20.2
69 F 2 0 1 16 NO 0 NO BRONCHITIS 1.78 56% YES MODERATE B YES 32 22.4
54 M 2 0 1 18 CURRENT 26 NO EMPHYSEMA 1.74 54% YES MODERATE B NO 33 23.5
58 M 1 0 1 12 CURRENT 21 NO BRONCHITIS 2.42 82% YES MILD B NO 36 23.1
62 M 2 0 1 18 FORMER 24 YES EMPHYSEMA 1.86 59% YES MODERATE B NO 33 24.6
66 M 3 0 1 25 FORMER 28 NO EMPHYSEMA 1.54 46% YES SEVERE B NO 34 27.4
59 M 1 1 2 8 FORMER 19 NO BRONCHITIS 1.45 42% YES SEVERE C NO 31 25.4
62 M 3 2 3 17 CURRENT 28 NO EMPHYSEMA 1.16 28% YES VERY SEVERE D NO 32 23.6
72 M 2 0 1 19 FORMER 31 YES EMPHYSEMA 1.96 54% YES MODERATE B NO 34 24.5
73 M 1 0 0 8 FORMER 31 NO BRONCHITIS 1.65 47% YES SEVERE A NO 33 23.1
65 M 2 0 2 18 FORMER 26 NO EMPHYSEMA 1.97 61% YES MODERATE D NO 34 23.5
68 M 2 1 1 16 FORMER 24 NO EMPHYSEMA 1.56 42% YES SEVERE D NO 36 22.5
56 M 2 1 1 18 CURRENT 22 NO EMPHYSEMA 1.55 40% YES SEVERE D NO 34 23.5
60 M 3 1 2 21 CURRENT 28 NO EMPHYSEMA 1.28 29% YES VERY SEVERE D NO 32 23.8
58 F 1 0 0 8 NO 0 YES BRONCHITIS 2.45 82% YES MILD A NO 34 26.5
65 F 2 0 1 17 NO 0 YES BRONCHITIS 2.14 62% YES MODERATE B NO 31 22.1
68 F 1 0 1 6 NO 0 YES EMPHYSEMA 1.86 56% YES MODERATE C NO 34 24.5
64 F 2 1 2 18 NO 0 YES EMPHYSEMA 1.65 46% YES SEVERE D NO 33 21.6
69 F 3 0 2 21 NO 0 YES EMPHYSEMA 1.45 38% YES SEVERE D NO 31 22.8
59 F 3 1 2 24 NO 0 YES EMPHYSEMA 1.23 27% YES VERY SEVERE D NO 33 25.7
67 F 2 0 1 15 NO 0 YES BRONCHITIS 2.15 64% YES MODERATE B NO 34 24.2
52 M 2 0 1 17 NO 0 NO BRONCHITIS 2.25 61% YES MODERATE B NO 36 23.7
55 M 2 0 1 18 NO 0 YES BRONCHITIS 1.65 46% YES SEVERE B NO 37 22.5
58 M 3 1 2 25 NO 0 NO EMPHYSEMA 1.24 29% YES VERY SEVERE D NO 35 20.3
63 M 2 0 1 15 NO 0 NO BRONCHITIS 2.14 63% YES MODERATE B NO 32 23.4
58 M 3 0 1 17 CURRENT 24 NO EMPHYSEMA 1.97 56% YES MODERATE B NO 33 14.3
65 M 2 1 1 19 CURRENT 28 NO EMPHYSEMA 1.65 44% YES SEVERE D NO 33 24.3
63 M 2 0 1 17 FORMER 25 NO BRONCHITIS 2.13 64% YES MODERATE B NO 34 25
53 M 1 0 1 8 CURRENT 17 NO BRONCHITIS 3.19 82% YES MILD A NO 35 24.6
66 M 3 1 1 23 FORMER 26 NO BRONCHITIS 1.67 43% YES SEVERE D NO 33 23.2
70 M 2 1 1 29 FORMER 27 NO EMPHYSEMA 1.97 56% YES MODERATE D NO 36 24.5
62 M 2 1 1 17 FORMER 25 NO EMPHYSEMA 1.45 41% YES SEVERE D NO 32 23.5
59 M 1 0 2 7 CURRENT 21 NO BRONCHITIS 2.1 59% YES MODERATE C NO 36 21.8
65 F 2 0 2 19 NO 0 YES EMPHYSEMA 1.56 41% YES SEVERE D NO 34 24.6
69 F 3 0 1 21 NO 0 YES EMPHYSEMA 1.18 26% YES VERY SEVERE B NO 34 21.9
59 F 2 1 1 18 NO 0 YES BRONCHITIS 1.65 48% YES SEVERE D NO 33 25.7
56 F 1 0 0 6 NO 0 YES BRONCHITIS 3.15 82% YES MILD A NO 33 23.4
62 F 2 0 1 19 NO 0 NO BRONCHITIS 2.16 65% YES MODERATE B NO 37 23.6
69 F 3 0 1 19 NO 0 YES EMPHYSEMA 1.78 49% YES SEVERE B NO 34 24.5
58 M 2 1 1 21 CURRENT 24 NO BRONCHITIS 1.96 62% YES MODERATE D NO 36 23.5
68 M 3 1 1 28 FORMER 27 NO EMPHYSEMA 1.24 29% YES VERY SEVERE D NO 38 24.6
55 M NA NA NA NA FORMER 20 NO NORMAL 3.54 88% NO NO NA NO 36 24.6
59 M NA NA NA NA CURRENT 27 NO NORMAL 4.14 90% NO NO NA YES 35 25.6
62 M NA NA NA NA CURRENT 25 NO NORMAL 3.98 86% NO NO NA NO 33 23.2
65 M NA NA NA NA FORMER 20 NO NORMAL 3.76 82% NO NO NA NO 34 24.6
67 M NA NA NA NA FORMER 15 NO NORMAL 3.94 86% NO NO NA NO 36 22.4
72 M NA NA NA NA FORMER 23 NO NORMAL 3.65 73% NO NO NA YES 32 24.3
57 M NA NA NA NA CURRENT 23 NO NORMAL 3.87 78% NO NO NA NO 33 23.5
61 M NA NA NA NA FORMER 20 NO NORMAL 3.98 86% NO NO NA NO 34 24.6
64 M NA NA NA NA FORMER 25 NO NORMAL 4.12 83% NO NO NA NO 37 23.2
67 M NA NA NA NA CURRENT 31 NO NORMAL 3.67 76% NO NO NA NO 34 24.5
71 M NA NA NA NA FORMER 27 NO NORMAL 3.87 78% NO NO NA NO 35 23.6
57 M NA NA NA NA CURRENT 23 NO NORMAL 3.56 72% NO NO NA NO 32 23.8
72 M NA NA NA NA FORMER 30 NO NORMAL 3.26 70% NO NO NA YES 33 23.9
69 M NA NA NA NA FORMER 26 NO NORMAL 3.56 78% NO NO NA NO 35 21.9
63 M NA NA NA NA CURRENT 28 NO NORMAL 3.86 82% NO NO NA NO 34 24.3
67 M NA NA NA NA FORMER 25 NO NORMAL 3.64 76% NO NO NA NO 32 23.3
71 M NA NA NA NA NO 0 NO NORMAL 3.87 83% NO NO NA NO 36 23.6
56 M NA NA NA NA NO 0 NO NORMAL 3.97 79% NO NO NA NO 35 24.6
61 M NA NA NA NA NO 0 NO NORMAL 4.17 84% NO NO NA NO 34 27.8
59 M NA NA NA NA NO 0 NO NORMAL 4.1 80% NO NO NA NO 35 26.8
67 M NA NA NA NA NO 0 NO NORMAL 3.68 78% NO NO NA NO 33 23.7
71 M NA NA NA NA NO 0 NO NORMAL 3.87 83% NO NO NA NO 36 23.6
56 M NA NA NA NA NO 0 NO NORMAL 3.97 79% NO NO NA NO 35 24.6
61 M NA NA NA NA NO 0 NO NORMAL 4.17 84% NO NO NA NO 34 27.8
59 M NA NA NA NA NO 0 NO NORMAL 4.1 80% NO NO NA NO 35 26.8
67 M NA NA NA NA NO 0 NO NORMAL 3.68 78% NO NO NA NO 33 23.7
58 M NA NA NA NA NO 0 NO NORMAL 3.89 76% NO NO NA NA 36 24.7
63 F NA NA NA NA NO 0 NO NORMAL 3.89 83% NO NO NA YES 38 23.7
68 F NA NA NA NA NO 0 NO NORMAL 4.14 86% NO NO NA NO 35 24.7
56 F NA NA NA NA NO 0 NO NORMAL 3.89 78% NO NO NA NO 34 21.9
63 F NA NA NA NA NO 0 NO NORMAL 3.89 83% NO NO NA YES 38 23.7
68 F NA NA NA NA NO 0 NO NORMAL 4.14 86% NO NO NA NO 35 24.7
56 F NA NA NA NA NO 0 NO NORMAL 3.89 78% NO NO NA NO 34 21.9
63 F NA NA NA NA NO 0 NO NORMAL 3.89 83% NO NO NA YES 38 23.7
68 F NA NA NA NA NO 0 NO NORMAL 4.14 86% NO NO NA NO 35 24.7
56 F NA NA NA NA NO 0 NO NORMAL 3.89 78% NO NO NA NO 34 21.9
63 F NA NA NA NA NO 0 NO NORMAL 3.89 83% NO NO NA YES 38 23.7
68 F NA NA NA NA NO 0 NO NORMAL 4.14 86% NO NO NA NO 35 24.7
56 F NA NA NA NA NO 0 NO NORMAL 3.89 78% NO NO NA NO 34 21.9
   FBS    BP TGL HDL-C ESR CIMT
CAROTID 
PLAGUE PAO2 PACO2 6MWD
BODE 
INDEX   PHT
RV 
DYSFUN
CTION
170 150/90 186 38 36 1.1 YES 75 52 323 5 MODERATE YES
110 140/90 166 42 18 0.7 NO 85 44 450 2 NO NO
106 130/80 156 45 18 0.6 NO NA NA NA NA NO NO
168 130/80 180 34 45 1.2 NO 68 50 230 4 SEVERE YES
114 120/80 143 48 23 0.6 NO 88 45 465 1 NO NO
123 110/70 156 50 26 0.65 NO NA NA NA NA NO NO
176 160/100 167 34 31 0.56 NO 83 44 380 2 NO NO
122 160/90 145 42 48 1.1 YES 64 54 240 6 SEVERE YES
106 120/80 136 45 18 0.53 NO NA NA NA NA NO NO
165 130/80 168 43 36 0.97 NO 76 47 270 2 MILD NO
178 150/90 146 36 52 1.23 YES 62 56 170 7 SEVERE YES
168 148/84 175 40 18 0.64 NO 82 44 450 0 NO NO
164 152/86 142 45 32 0.87 NO 75 47 245 4 MILD NO
145 164/94 189 46 42 1.18 NO 68 51 188 6 MODERATE YES
120 178/96 156 44 44 1.24 YES 66 53 176 5 SEVERE YES
176 146/88 180 34 56 1.28 YES 62 57 148 8 SEVERE YES
152 154/86 178 45 34 1.04 NO 72 48 280 2 MILD NO
174 162/96 135 42 21 0.63 NO 82 42 356 0 NO NO
116 170/98 190 36 35 0.98 NO 68 40 267 3 MILD NO
168 124/68 159 42 46 1.18 NO 63 54 197 6 MODERATE NO
124 130/78 198 34 44 1.16 NO 76 46 265 3 MILD NO
168 154/86 132 36 48 1.25 YES 60 57 158 7 MODERATE YES
165 140/90 178 34 46 0.96 NO 78 43 330 1 NO NO
186 154/88 154 45 40 1.04 NO 64 54 220 4 NO YES
136 152/86 176 35 33 1.16 YES 60 52 189 6 MODERATE YES
116 154/90 169 33 54 1.29 NO 58 57 143 9 SEVERE YES
178 140/88 176 39 51 1.26 YES 56 59 168 8 SEVERE YES
198 126/76 188 33 32 1.17 NO 76 54 188 7 MODERATE NO
165 136/84 166 42 43 1.02 NO 78 52 257 5 MODERATE NO
178 148/86 188 38 38 1.14 NO 68 48 267 4 MILD YES
120 164/76 165 34 32 0.72 NO 78 45 245 7 SEVERE YES
179 150/90 158 38 36 0.54 NO 83 44 321 2 NO NO
166 140/90 169 42 15 0.63 NO 81 45 285 3 MILD NO
197 150/86 176 38 19 0.62 NO 84 46 310 3 MODERATE NO
145 146/84 183 36 15 0.69 NO 82 43 284 1 NO NO
156 136/84 164 32 18 0.71 NO 83 45 234 1 NO NO
168 154/90 186 38 24 0.78 NO 84 42 187 3 MILD NO
178 160/90 166 41 28 0.88 NO 82% 46 210 2 MILD NO
189 156/84 188 37 38 1.06 NO 66 52 186 6 MODERATE YES
155 166/88 169 33 44 1.1 YES 60 54 166 6 MODERATE NO
167 144/84 178 35 51 1.23 YES 56 58 145 9 SEVERE YES
188 164/88 176 33 45 1.2 YES 64 56 168 4 MODERATE no
176 142/80 168 31 46 1.22 yes 62 55 143 7 MODERATE YES
188 156/64 174 34 25 0.92 NO 74 49 235 3 MILD NO
158 160/86 188 31 32 1.04 NO 68 50 186 5 MODERATE NO
190 166/88 176 32 42 1.12 NO 62 54 164 6 MODERATE NO
198 140/74 166 32 43 1.27 YES 58 59 132 9 SEVERE YES
187 150/90 186 36 32 1.06 NO 66 52 245 4 MODERATE NO
116 134/74 143 42 28 0.86 NO 68 46 321 3 MILD NO
146 124/72 164 45 21 0.91 NO 74 44 388 1 NO NO
167 134/68 133 42 25 0.93 NO 76 48 324 3 MILD NO
114 116/82 168 41 28 0.97 NO 65 51 275 5 MODERATE YES
128 120/76 145 43 31 1.03 NO 68 48 289 3 MILD NO
164 110/76 142 45 38 1.05 YES 60 54 210 7 MODERATE YES
110 156/86 165 47 26 0.83 NO 76 48 289 3 NO NO
144 154/80 123 43 24 0.88 NO 76 49 265 3 NO NO
129 148/88 145 44 32 0.93 NO 68 51 215 4 MILD NO
168 126/76 134 45 35 0.98 NO 62 52 190 5 MILD NO
145 146/78 143 43 32 1.02 NO 66 50 215 5 MODERATE NO
116 156/88 122 45 41 1.08 NO 62 55 167 7 SEVERE YES
118 120/80 165 42 23 0.86 NO 86 44 328 1 NO NO
143 110/80 143 51 26 0.9 NO 76 47 256 3 MILD NO
120 130/78 156 56 21 0.88 NO 78 48 289 2 NO NO
145 140/88 145 51 28 0.94 NO 68 50 221 5 MODERATE NO
120 156/86 144 41 32 1.04 NO 66 48 214 6 MODERATE NO
117 140/90 134 54 41 1.09 YES 58 54 158 8 SEVERE YES
98 136/88 167 52 21 0.83 NO 76 44 315 3 MILD NO
116 140/78 134 46 25 0.87 NO 78 43 365 2 NO NO
106 130/78 143 47 26 0.94 NO 68 48 265 4 MILD NO
108 140/90 143 42 36 1.04 NO 60 53 189 7 MODERATE YES
120 136/88 134 45 23 0.54 NO 78 45 278 3 MILD NO
114 124/78 145 45 22 0.64 NO 76 47 289 4 MILD NO
120 140/90 123 43 26 0.71 NO 68 48 235 5 MODERATE NO
116 130/80 145 45 28 0.67 NO 78 43 345 3 NO NO
167 120/76 143 46 21 0.65 NO 82 45 388 0 NO NO
123 140/90 134 43 34 0.74 NO 67 51 212 6 MODERATE NO
116 150/90 132 44 24 0.68 NO 74 48 298 3 MILD NO
120 140/86 145 45 32 0.72 NO 66 49 243 5 MODERATE NO
145 114/74 132 46 25 0.65 NO 70 50 267 2 NO NO
120 116/80 168 51 29 0.71 NO 75 49 213 5 MODERATE NO
117 140/90 165 53 36 0.74 NO 62 52 189 7 SEVERE YES
156 138/90 138 51 27 0.63 NO 66 48 198 5 MODERATE NO
145 120/70 187 45 18 0.56 NO 84 43 399 0 NO NO
143 116/76 143 52 21 0.65 NO 78 47 289 3 MILD NO
120 130/78 187 51 28 0.72 NO 65 49 234 6 MODERATE NO
114 140/88 123 46 28 0.69 NO 75 45 278 3 MILD NO
118 142/80 143 47 32 0.72 NO 62 53 165 7 SEVERE YES
135 126/78 167 46 23 0.65 NO NA NA NA NA NO NO
156 140/90 178 36 18 0.84 NO NA NA NA NA NO NO
120 124/72 132 45 16 0.56 NO NA NA NA NA NO NO
115 116/78 145 42 18 0.88 NO NA NA NA NA NO NO
148 124/78 146 45 25 0.65 NO NA NA NA NA NO NO
168 138/90 165 38 24 0.86 NO NA NA NA NA NO NO
122 128/76 123 45 19 0.67 NO NA NA NA NA NO NO
114 140/68 134 43 22 0.62 NO NA NA NA NA NO NO
116 116/78 128 46 16 0.56 NO NA NA NA NA NO NO
112 136/84 145 42 24 0.89 NO NA NA NA NA NO NO
118 140/80 134 43 26 0.64 NO NA NA NA NA NO NO
98 130/88 145 45 23 0.68 NO NA NA NA NA NO NO
145 140/90 167 38 34 0.7 NO NA NA NA NA NO NO
144 128/78 134 45 21 0.58 NO NA NA NA NA NO NO
120 136/88 138 43 25 0.69 NO NA NA NA NA NO NO
138 114/76 156 46 28 0.59 NO NA NA NA NA NO NO
90 120/78 122 42 17 0.63 NO NA NA NA NA NO NO
118 116/76 144 45 26 0.91 NO NA NA NA NA NO NO
135 118/80 135 42 23 0.71 NO NA NA NA NA NO NO
118 120/78 145 45 26 0.63 NO NA NA NA NA NO NO
117 120/88 133 43 28 0.68 NO NA NA NA NA NO NO
90 120/78 122 42 17 0.63 NO NA NA NA NA NO NO
118 116/76 144 45 26 0.91 NO NA NA NA NA NO NO
135 118/80 135 42 23 0.71 NO NA NA NA NA NO NO
118 120/78 145 45 26 0.63 NO NA NA NA NA NO NO
117 120/88 133 43 28 0.68 NO NA NA NA NA NO NO
114 130/78 145 44 24 0.65 NO NA NA NA NA NO NO
156 140/90 156 43 27 0.85 NO NA NA NA NA NO NO
168 142/78 138 52 23 0.67 NO NA NA NA NA NO NO
122 122/78 144 45 25 0.56 NO NA NA NA NA NO NO
156 140/90 156 43 27 0.85 NO NA NA NA NA NO NO
168 142/78 138 52 23 0.67 NO NA NA NA NA NO NO
122 122/78 144 45 25 0.56 NO NA NA NA NA NO NO
156 140/90 156 43 27 0.85 NO NA NA NA NA NO NO
168 142/78 138 52 23 0.67 NO NA NA NA NA NO NO
122 122/78 144 45 25 0.56 NO NA NA NA NA NO NO
156 140/90 156 43 27 0.85 NO NA NA NA NA NO NO
168 142/78 138 52 23 0.67 NO NA NA NA NA NO NO
122 122/78 144 45 25 0.56 NO NA NA NA NA NO NO
